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Hepatocellular carcinoma (HCC) is the fifth most common cancer in 
the world.  Chronic Hepatitis B Virus (HBV) infection is epidemiologically 
associated with the development of HCC but its role in HCC remains poorly 
understood due to technological limitations.  However, it was proposed that 
HBV may contribute to HCC via integration of its genome into the host 
genome, causing either the “cis” or “trans” effects. 
Preliminary study from our laboratory focusing on characterizing the 
smallest gene of HBV, the X (HBx) gene, revealed that the 3’-end of the HBx 
gene may not be always intact in HCC samples and the nucleotide sequences 
between HBx derived from the non-tumor and tumor samples are different.  
These interesting findings directed us to systematically characterize the entire 
HBV genome in HCC patients.  First, we set up a strategy to enrich for HBV 
DNA sequences from the genomic DNA of 48 HCC patients using an oligo-
bead-based strategy.  The HBV-enriched DNA samples were then pooled and 
sequenced using the Genome Sequencer FLX (GS-FLX).   
For a long time, HBV integration has been suggested to be a random 
event.  However, in this study, we observed preferential integration of HBV 
into promoters of genes (P<0.001) and chromosome 10 (P<0.01) in the tumor 
samples.  Importantly, integration into chromosome 10 was significantly 
associated with poorly differentiated tumors (P<0.05).  Notably, in the tumors, 
recurrent integration into the promoter of the human telomerase reverse 
transcriptase (TERT) gene was found to correlate with increased TERT 
expression.  In addition, integration events in genic region are significantly 
(P<0.05) associated with differential expressions of the affected genes 
vii 
compared to integration events in intergenic region.  Remarkably, integration 
events in the tumor but not non-tumor samples are frequently found to affect 
genes in critical cellular pathways such as cell cycle, cell death and survival 
and DNA replication, recombination and repair.   
With regards to the viral genome, the preferred region within the HBV 
genome involved in integration is at the 3’-end of HBx where viral 
replication/transcription initiates suggesting that viral integration may occur 
via replication/transcription intermediates.  HBx-host chimeric transcripts 
represent the most common type of chimeric transcripts.  These chimeric 
transcripts can be expressed as chimeric proteins which were found to 
abrogate the growth suppressive ability of full length HBx implying that these 
HBx mutants may have a role to play in the first step of carcinogenesis.  
The HBV genome was also found to be highly altered at the structural 
level in HCC samples.  The most commonly observed alterations are deletions 
and inversions.  Interestingly, the region within the viral genome preferentially 
involved in integration events was also found to be enriched for viral structural 
alteration events suggesting that both HBV integration and structural 
alterations may occur via viral replication/transcription intermediates.  These 
alteration events within the HBV genome may also contribute to the 
frequently observed deletion/disruption of the 3’-end of the HBx gene. 
Sequence variation resulting in non-conservative amino acid 
substitutions are commonly observed in the HBV genome especially in the 
HBx of genotype C.  These substitutions may have the potential to affect the 
properties or structures of the viral proteins and hence alter their function.   
viii 
In conclusion, this study presents a systematic characterization of HBV 
in HCC samples.  We demonstrated that HBV may act primarily as an 
insertional mutagen by affecting the regulations of critical cellular genes.  
HBV proteins especially the mutant HBx protein may contribute to HCC 
possibly by playing a role in the early step of carcinogenesis. 
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CHAPTER 1: INTRODUCTION 
1.1 Hepatocellular Carcinoma (HCC) 
1.1.1 Epidemiology 
Liver cancer is the 5th and 8th most common cancer in men and 
women, respectively with a mortality rate similar to its incidence rate (Figure 
1.1).  With more than 600,000 deaths annually, it is ranked the third leading 
cause of cancer-related deaths worldwide [1-5].  Hepatocellular Carcinoma 
(HCC) is the most common form of liver cancer.  About 80% of HCC cases 
occur in Eastern and South-Eastern Asia, Middle and Western Africa with 
incidence rates of more than 20 per 100,000 individuals (Figure 1.2).  HCC is 
also a disease with poor prognosis mainly due to its late manifestation of 
symptoms and unresponsiveness to treatments [5].  Currently, the most 
effective treatments for HCC are surgical resection and liver transplantation 
[6,7].  However, the number of resectable cases is small, due to the multi-
focality of tumor, early vascular invasion and concurrent liver cirrhosis.  In 
addition, therapies that can prolong life for up to a few years are only available 
in developed countries, while most HCC patients in developing countries die 






Figure 1.1: The incidence and mortality of the most frequent cancers 
worldwide.  Cancer incidence and mortality are plotted as bar charts and 
ranked according to overall incidence in males (top) and females (bottom). 
The liver cancer incidence in males and females are highlighted in black boxes. 
Incidence: Population weighted average of the country rates applied to the 
2008 area population.  Mortality: Population weighted average of the country 
rates applied to the 2008 area population. Age-standardized rate, ASR (W): A 
rate is the number of new cases or deaths per 100 000 persons per year.  An 
age-standardized rate is the rate that a population would have if it had a 
standard age structure.  (Reprinted by permission from Ferlay J, Shin HR, 
Bray F, Forman D, Mathers C and Parkin DM. GLOBOCAN 2008, Cancer 
Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. 







Figure 1.2: The incidence of liver cancer worldwide. The geographical 
distribution of liver cancer incidence in males (top) and females (bottom) are 
highlighted with colors of different intensities.  Higher intensity represents 
higher incidence rate.  The regions of high incidence are Eastern and South-
Eastern Asia, Middle and Western Africa as highlighted in intense red color.  
Unit of measurement: 100,000.  (Reprinted by permission from Ferlay J, Shin 
HR, Bray F, Forman D, Mathers C and Parkin DM. GLOBOCAN 2008, 
Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 




HCC is a complex disease that occurs through a multi-step process.  
Multiple risk factors have been suggested to contribute to HCC including 
Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) infection, chronic 
alcohol consumption and aflatoxin B1 exposure, as well as some minor risk 
factors such as tobacco exposure, obesity, and rare genetic disorder e.g. 
hemochromatosis [8].  Among these, chronic Hepatitis Virus infection 
represents the most strongly associated risk factor thus far.  
1.1.2.1 HBV INFECTION 
Approximately 5% of world population (~400 million people) are 
chronic HBV carriers (characterized by persistence of HBsAg in the plasma 
over a period of 6 months) and about 1 million people die per year due to 
HBV-associated liver pathologies [9].  It is estimated that over 20% of the 400 
million chronic HBV carriers will develop HCC [10,11] and more than 50% of 
HCC cases worldwide are caused by chronic HBV infection [12].  The overlap 
between geographical distribution of chronic HBV infection (Figure 1.3) with 
that of liver cancer incidence (Figure 1.2) further implies the  etiological link 
between HBV infection and HCC.  In addition, the nationwide vaccination 
program against HBV in the 1980s has successfully reduced both the number 
of HBV carriers and the incidence of HCC in children in Taiwan [13], 
providing further evidence for HBV as an etiological factor for HCC.   
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Figure 1.3: Geographic distribution of chronic hepatitis B virus (HBV) 





Together with HCV, HBV infection was ranked as one of the top 
preventable causes of global mortality by Weiss and McMichael [14] (Figure 
1.4).  Despite the availability of effective vaccines since two decades ago, 
poor compliance with immunization programs in the less developed areas due 
to ignorance or poverty has limited the effective eradication or prevention of 
HBV infection.  In addition, occult HBV infection which was defined as the 
presence of viral DNA in the liver, with absence of HBsAg and low titer or 
even absence of HBV DNA in the serum [15] may also contribute to the 
burden of HBV-related diseases and is a major concern for transfusional 
medicine and transplantation [16].  Therefore, chronic HBV infection remains 
an immense threat to global health. 
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Figure 1.4: Relative importance of preventable causes of death as 
determined by their estimated impact on mortality. The values are 
approximate global death rates for the year 2003, taken from the World Health 
Organization (WHO) and other sources.  HBV, hepatitis B virus; HCV, 
hepatitis C virus; HPV, human papillomavirus; SARS, severe acute respiratory 
syndrome; TB, tuberculosis; vCJD, variant Creutzfeldt-Jakob disease. 
(Reprinted by permission from Nature Publishing Group Nat. Med. Weiss RA 
and McMichael AJ, 2004 [14]) 
 
1.1.2.2 HCV INFECTION 
HCV is an RNA virus that belongs to the family flaviviridae [17].  
Globally, about 2% of population (~180 million people) are infected by HCV 
and about 25% of HCC cases worldwide are related to chronic HCV infection 
[16].  HCV is thought to cause HCC through the stage of cirrhosis.  A 
significant increase in the incidence of HCC was observed in HCV-infected 
cohorts compared with HCV-negative cohorts in prospective studies [18].  In 
addition, it was found that infection with HBV and HCV alone had an odds 
ratio of 23 and 17, respectively, while co-infection with HBV and HCV had an 
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odds ratio of 165 for HCC [19], suggesting that there is a synergistic effect 
between HBV and HCV infections.  While HBV is the most frequently 
reported etiologic factor among the HCC patients in Asia, HCV is more 
commonly reported as the etiologic factor in Hispanics and African Americans 
with HCC.  
1.1.2.3 ALCOHOL 
Chronic alcohol consumption has been well established as a risk factor 
for HCC [20-22].  The underlying mechanism is believed to be related to 
cirrhosis caused by chronic alcohol consumption.  During the period when the 
damaged liver cells are trying to heal by active regeneration, the chances for 
genetic alterations to occur and accumulate are greatly increased hence 
contributing to HCC.  Many of the alcoholic related HCC are also associated 
with chronic HBV or HCV infection, suggesting the possible synergistic 
interaction between these risk factors [10].  In addition, it was also reported 
that there is significant synergistic interaction between alcohol, tobacco 
exposure and obesity in increasing the risk of HCC [11]. 
1.1.2.4 AFLATOXIN B1 (AFB1) 
AFB1 is a potent hepatocarcinogen produced by fungi of the 
Aspergillus species that grows readily on foodstuffs stored in damp conditions 
[23]. When ingested, AFB1 is metabolized into the active AFB1-exo-8,9-
epoxide, which binds and cause damage to DNA.  The characteristic genetic 
change associated with AFB1 is a G  T transversion causing a mutation at 
serine 249 in the p53 gene [16] which is observed in ~50% of tumors from 
AFB1-endemic regions such as Southern Africa [24] and Qidong, China [25].  
There are also strong evidences suggesting a synergistic interaction between 
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chronic HBV infection and dietary aflatoxin exposure in HCC development 
[26-28].   
1.2 HBV and HCC 
1.2.1 HBV Virology 
HBV is a member of the Hepadnaviridae family which represents the 
smallest DNA-containing, enveloped animal viruses known so far [29].  Other 
closely related viruses of the hepadnavirus family include the woodchuck 
hepatitis virus (WHV) [30] and the ground squirrel hepatitis virus (GSHV) [31] 
which also induce chronic liver disease and a high frequency of liver tumors in 
the hosts.  HBV is characterized by their liver tropism, high species specificity 
and a unique genomic organization and replication mechanism.  The virion 
(sometimes referred to as “Dane particles”) which has a spherical structure of 
42-44nm in diameter consists of an outer lipid envelope (Hepatitis B surface 
antigen, HBsAg) and an icosahedral nucleocapsid which is formed by the core 
protein (HBcAg). The nucleocapsid encloses the viral DNA and a DNA 
polymerase (Figure 1.5). 
-
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Figure 1.5: Structure of Hepatitis B Virion.  The virion (Dane particle) has 
a spherical structure of 42-44nm in diameter consists of Hepatitis B surface 
antigen (HBsAg) and an icosahedral nucleocapsid which is formed by the core 
protein (HBcAg).  The nucleocapsid encloses the viral DNA and a DNA 
polymerase.  (Adapted from 
http://en.wikipedia.org/wiki/Transmission_of_hepadnaviruses, free license 
from Wikimedia Commons) 
 
1.2.2 HBV Genome 
As shown in Figure 1.6, the encapsidated viral genome is a relaxed 
circular partially double-stranded DNA (rcDNA) of around 3.2kb, covalently 
linked to the terminal protein of the viral polymerase.  The two strands are 
held in a circular configuration by cohesive overlapping of the 5’ ends of the 
strands, which contain two direct repeats, DR1 and DR2.  The HBV genome 
contains four overlapping open reading frames (ORFs), namely the preS/S 
encoding the three viral surface proteins (PreS1, PreS2 and S proteins) sharing 
the same C-terminal domain, the precore/core (PreC/C) encoding the core 
protein and the non-structural precore protein which undergoes cleavage of N-
terminal signal to form the secreted 17kDa HBeAg, the polymerase ORF 
encoding the viral polymerase, which possesses reverse transcriptase, DNA 
polymerase and RNase H activities, and the terminal protein for priming and 
lastly, the X ORF, encoding the smallest protein termed the X protein which 
has regulatory function and is important for viral replication in vivo [32,33].  
Four transcripts including the 3.5kb (PreC/C and pgRNA), 2.4kb (PreS1), 
2.1kb (PreS2/S) and 0.7kb (X) transcripts are produced from the viral genome.  









Figure 1.6: Structure of HBV genome.  The 3.2 kb, partially double-
stranded circular HBV genome carries four open reading frames (black arrows) 
including the preS/S ORF encoding the three viral surface proteins (PreS1, 
PreS2 and S proteins), precore/core (PreC/C) ORF encoding the core protein 
and the HBeAg, the polymerase ORF encoding the viral polymerase and the 
terminal protein as well as the X ORF encoding the X protein.  The two 
strands are held in a circular configuration by cohesive overlapping of the 5’ 
ends of the strands, which contain two direct repeats, DR1 and DR2.  Four 
transcripts (outer blue arrows) including the 3.5kb (PreC/C and pgRNA), 
2.4kb (PreS1), 2.1kb (PreS2/S) and 0.7kb (X) transcripts are produced from 
the viral genome.  All transcripts terminate at a common site within the core 
gene. 
 
1.2.3 HBV Life Cycle 
As shown in Figure 1.7, the process of HBV infection involves the 
binding of the virus to an unknown hepatocyte-specific receptor [34,35].  
Upon viral entry and uncoating of the virus, the HBV genome (rcDNA) gets 
released into the cell nucleus by accumulation of capsids at the nuclear pore 
complex [36].  In the nucleus, the covalently attached terminal protein is 
removed and the positive DNA strand is repaired to form a complete super-
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coiled covalently-closed circular DNA (cccDNA) molecule probably by the 
host cell DNA repair enzymes, including topoisomerases I and II [37].  After 
incorporation of cellular histone and non-histone proteins, the cccDNA is 
camouflaged as a minichromosome and is hence undetectable by host innate 
immune defense mechanisms.   
Using the cccDNA as template, the virus then utilizes the host cellular 
transcriptional machinery to produce all the transcripts necessary for viral 
protein production as well as viral replication (pregenomic RNA or pgRNA).  
The viral transcripts are then translated in the cytoplasm to produce the viral 
surface, core, polymerase, and X proteins.  The progeny viral capsids then 
assemble in the cytoplasm, incorporating the pgRNA (RNA packaging) along 
with the HBV polymerase.  The pgRNA is then reverse transcribed by the 
reverse transcriptase of HBV polymerase to form the negative (-) strand and 
the RNA template is then degraded by the RNase H activity of polymerase.  
Subsequently, the positive (+) strand of the viral genome is synthesized from 
the negative strand by the DNA polymerase activity of the HBV polymerase 
within the newly formed nucleocapsid.  The resulting nucleocapsid can either 
bud into the endoplasmic reticulum to be enveloped with surface antigen and 
released from the cell as new virion or recycle their genome into the nucleus to 
produce additional cccDNA.  
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Figure 1.7: The Replication Cycle of HBV.  HBV virions bind to hepatocyte 
surface receptors and are internalized.  Viral core particles then attach to and 
enter the nucleus, where their rcDNA genomes are repaired to form a 
covalently closed circular DNA (cccDNA) which serves as the template for 
the transcription of viral RNA, including the 3.5kb (PreC/C and pgRNA), 
2.4kb (PreS1), 2.1kb (PreS2/S) and 0.7kb (X) transcripts.  The viral transcripts 
are then translated in the cytoplasm to produce the viral surface, core, 
polymerase, and X proteins.  The progeny viral capsids then assemble in the 
cytoplasm, incorporating the pgRNA along with the HBV polymerase. The 
pgRNA is then reverse transcribed into viral DNA within the newly formed 
nucleocapsid.  The resulting nucleocapsid can either bud into the endoplasmic 
reticulum to be enveloped and released from the cell as new virion or recycle 
their genome into the nucleus for conversion to cccDNA (Reprinted by 
permission from BMJ Publishing Group Ltd. Gut Dandri M and Locarnini S, 
2012 [29]) 
 
1.2.4 HBV Genome Variability 
Due to its long existence, HBV has evolved into multiple genetic 
strains that are present at different prevalence in different parts of the world.  
Eight distinct genotypes (A-H) of HBV which genomic sequences differ from 
each other by >8% have been identified [38-41].  Within some of these 
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genotypes, subgenotypes have been described, with a minimum genetic 
divergence of 4%, such as A1-A6, B1-B8, C1-C7, D1-D7 and F1-F4 in 
genotypes A, B, C, D and F, respectively [42-52].  The different HBV 
genotypes have different geographical distribution (Table 1.1).  In South East 
Asia, genotypes B and C are the most prevalent strains identified.  The 
different genotypes/subgenotypes have been associated with the severity or 
outcome of HBV-associated liver diseases as well as the response to antiviral 
therapies [53-57].  For example, it was suggested that the severity and 
outcome of chronic Hepatitis B are more serious in patients infected with 
HBV of genotype C compared to B [58-61]. 
Table 1.1: Geographical Distribution of HBV Genotypes [16] 
Genotype Major geographic distribution areas
A North-West Europe, North America, South Africa
B South East Asia, China, Japan
C South East Asia, China, Korea, Japan, Polynesia
D Mediterranean area, Middle East, East Europe, India
E West and Central Africa
F South America, Alaska, Polynesia
G France, United States
H Central America, Mexico, South United States  
 
1.2.4.1 MUTATIONS IN HBV GENOME 
Mutations at specific sites within the HBV genome have also been 
identified and frequently associated with poorer clinical outcomes.  One of the 
reasons for the occurrence of these mutations is probably due to the absence of 
proof reading capability of the HBV polymerase during viral genome 
replication.  Other than the spontaneous errors generated during replication, 
the mutations might also arise due to the selection pressure imposed by the 
host immune system and/or exogenous factors such as vaccination or drug 
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therapy [16].  Mutations have been reported in all 4 HBV genes but those in 
the precore/core, surface and polymerase regions had been more fully 
characterized [62].  
1.2.4.1.1 Precore and Core Mutations 
As the core protein is a major recognition target for cytotoxic T cells, a 
key player in viral clearance, mutations within this gene may contribute to 
immune escape, leading to chronic HBV infection.  Among the various 
mutations identified, the G1896A and A1762T/G1764A are the most 
commonly reported mutations in the precore and basal core promoter region 
respectively.  The precore G1896A mutation results in failure of HBeAg 
production by introducing a premature stop codon into the ORF of 
precore/core [63,64].  This mutation is particularly prevalent in Asia, Africa, 
Southern Europe and the Middle East where 47-60% of isolates from patients 
with chronic active hepatitis carry this mutation [65].  The A1762T/G1764A 
mutations in the basal core promoter (BCP mutant) have been described in 
patients with chronic HBV [66] and fulminant hepatitis [67].  This BCP 
mutant results in diminished production of HBeAg by 70% and may enhance 
viral genome replication in vitro [66].  These mutations are also significantly 
associated with the development of HCC, both in genotypes B and C [68].  As 
the basal core promoter (BCP) overlaps with the X gene, the mutations in the 
BCP also result in amino acid changes at positions 130 (K130M) and 131 
(V131I) of the X protein which have been proposed as prognostic markers for 
HCC development [69].  In HBV of genotype C, it was found that C1653T in 
enhancer II as well as T1753V and A1762T/G1764A in the basal core 
promoter (BCP) can either alone or in combination predict HCC development 
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in 80% of cases [70].  Furthermore, the A1762T/G1764A mutation can be 
detected in plasma up to 8 years before HCC diagnosis which suggests the 
possibility of this mutation as a strong predictive biomarker [69]. 
1.2.4.1.2 Surface Mutations 
The mutations in the surface antigen are clinically important as 
incidence of vaccine escape mutants have been reported [71,72].  These 
mutants typically carry substitutions within the “a” determinant, preventing 
the epitope from being recognized by the antibodies generated against the 
wild-type HBsAg [73,74].  The “a” determinant is located within the major 
hydrophilic region of the HBsAg and serves as the major immune target for 
the HBs polyclonal antibody [73,74].  
1.2.4.1.3 Polymerase Mutations 
Mutations in the polymerase gene are mostly associated with 
treatments of drugs such as lamivudine and famciclovir which are mainly RT 
inhibitors.  On exposure to lamivudine, amino acid changes occur at codon 
528 (the template binding site of the polymerase or Region B) or codon 552 of 
the YMDD motif (the catalytic site of the polymerase or Region C), and 
significantly decrease the efficacy of lamivudine [75,76].  Several mutations 
(V521L, P525L, L528M, T532S, and V555I) have also been associated with 
famciclovir treatment, some of which show decreased sensitivity to the drug in 
vitro [77,78]. 
1.2.5 Major mechanisms by which HBV contributes to HCC 
HBV is thought to contribute to HCC via two major mechanisms.  The 
first mechanism involves continuous immune-mediated destruction and 
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subsequent regeneration of hepatocytes during chronic HBV infection which 
facilitate the accumulation of mutations favoring cellular transformation.  The 
second mechanism involves the integration of subgenomic viral genome into 
the host genome causing either the “cis” or the “trans” effects.  The “cis” 
effects include the cis-activation of tumor-promoting genes or 
disruption/inactivation of tumor suppressor genes while the “trans” effects 
involve the expression of various HBV proteins such as the HBx and the 
PreS2 or mutant viral proteins that modulate gene expression and altering 
intracellular signaling pathways. 
1.2.5.1 CHRONIC INFLAMMATION INDUCED BY HBV 
As HBV is not directly cytopathic, liver injury associated with chronic 
HBV infection is mostly caused by repeated attempts of the host’s immune 
responses to control the infection [29].  Recurring cycles of hepatocyte 
necrosis and regeneration during viral-induced chronic necroinflammation can 
markedly increase hepatocyte turnover rates as well as the probability of 
genomic alterations [79].  During the process, some cells may reactivate 
telomerase activity and become immortalized and may then continue to 
accumulate additional genetic and epigenetic changes that eventually lead to 
malignant transformation.  Moreover, an accelerated cell division rate also 
prevents some of the mutated or damaged DNA to be repaired before the cell 
divides again [80].  Thus, the damages may be passed on to the daughter cells 
which if escape elimination by apoptosis and accumulate more mutations over 
time, may become tumor.  In addition, hepatic inflammation itself causes the 
release of proinflammatory cytokines, which results in the local production of 
reactive oxygen species that have been implicated in oncogenesis [81].   
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Nonetheless, about 20% of all HBV-related HCC develop in non-
cirrhotic livers and in some cases even without signs of chronic hepatitis 
[82,83], suggesting that HBV might play a direct pro-oncogenic role.  
1.2.5.2 HBV INTEGRATION INTO HOST GENOME 
Although high cccDNA copy number is detected in chronically 
infected duck and woodchuck livers [84,85], lower cccDNA copy number is 
detected in human liver biopsies (median 0.1-1 cccDNA copy/cell), suggesting 
that the complex interplay of host and viral factors may control the cccDNA 
pool size in infected hepatocytes [86-88].  The low intrahepatic cccDNA loads 
is attributable to the lack of centromere structures which ensure correct 
migration during mitosis, leading to drastic cccDNA loss during hepatocyte 
proliferation.  Therefore, HBV tends to retain its genome in the host cells by 
integrating its genome into the host genome. 
Although there is no evidence showing that HBV integration into the 
host genome per se can lead to HCC, studies have shown that HBV genome 
integrations are present in over 85-90% of HBV-related HCCs and usually 
precede the development of HCC [37,89-95].  Moreover, it was found that 
HBV-induced HCC can occur in the context of a non-cirrhotic liver in 
chronically-infected children and young adults suggesting that HBV may have 
some independent roles in liver carcinogenesis possibly through integrating its 
genome into the host genome [96,97].   
Integration of HBV into the host genome can have two potential 
consequences: (1) the “cis” effect when the viral DNA insertion causes the 
host genome to be disrupted or rearranged leading to changes in structure or 
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function of the cellular gene products or deregulation of the expression of the 
genes at or near the integration sites (2) the “trans” effect when either 
wildtype or altered viral proteins are expressed from the integrated viral 
genome and affect the expression of host genes or intracellular signaling 
pathways. 
1.2.5.2.1 “Cis” Role of HBV in HCC Development 
The first piece of evidence for the possible “cis” role of hepatitis virus 
is demonstrated by the woodchuck hepatitis virus, which preferentially 
integrates its genome into the c-Myc, N-myc1 or N-myc2 oncogenes loci 
in >80% of woodchuck hepatitis virus-induced cancers [98-102].  However, 
there is no report showing strong preference for human HBV integrations into 
the myc or any other locus.  Nonetheless, there are studies showing that HBV 
integrations occur in or adjacent to genes that play important roles in 
oncogenesis.  Some examples include the RARβ [103], cyclin A2 [104], 
SERCA1 [105], MLL2/MLL4 [106-108] and TERT [105,107,109-113].  
However, among these, only the MLL4 and TERT genes were found to be 
recurrently targeted by HBV integration in more than one individual.  Similar 
to WHV which is able to cis-activate the myc oncogenes, strong viral 
enhancers present in the HBV genome [114,115] have been suggested to be 
preferentially retained in the integrated HBV DNA and are able to cis-activate 
cellular genes [109,116].  In addition, there are also evidences suggesting that 
some of the integration events cause partial deletions, duplications or 
rearrangements of cellular DNA [117-122].  However, these observations are 
poorly reproducible.  Since integration events in or near important cellular 
genes have been identified using PCR-based methods and traditional Sanger 
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sequencing, although at low frequency, it is worthwhile to analyze a larger 
cohort of patients to determine the cellular genes affected by HBV integration, 
in order to assess the “cis” role of HBV integration. 
1.2.5.2.2 “Trans” Role of HBV in HCC Development 
Other than the “cis” effects, viral integration into the host genome or 
other rearrangements in the viral genome may also lead to expression of either 
wildtype or altered HBV proteins, such as viral-host chimeric proteins or 
truncated viral proteins.  Two examples of HBV proteins reported to be 
implicated in HCC are the PreS2 and the HBx transcriptional activators [123]. 
1.2.5.2.2.1 PreS2 Activators 
The HBV surface gene open reading frame is divided into three coding 
regions: preS1, preS2 and S, each starting with an in-frame start codon.  Large 
(LHBs: PreS1+PreS2+S), Middle (MHBs: PreS2+S) and Small (SHBs: S) 
surface proteins can be produced through the alternate translation initiation at 
each of the three start codons.  The LHBs has been reported to be a 
transcriptional activator [124] and transgenic mice that overproduce LHBs in 
the liver develop liver tumors [125].  In contrast, the full length MHBs 
displays no transcriptional activator function.  However, when the 3’-end of 
the preS2/S gene encoding at least the last 70 amino acids is deleted, a 
functional transcriptional activator MHBs
t
 is generated [126].  The deletions 
of 3’-end of the preS2/S gene generating functional MHBst were found in a 
significant number of integrates suggesting the implication of this 
transcriptional activator in HBV-related HCC [123,127].  Specifically, the 
MHBs truncated at amino acid 76, MHBs
t76
, was reported to activate the c-
Raf-1/Erk2 signaling resulting in an increased proliferation rate of hepatocytes 
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and an increased incidence of liver tumor in MHBs
t
 transgenic mice older than 
15 months was observed, suggesting that preS2 transactivator plays an 
important role in tumorigenesis [128].  
1.2.5.2.2.2 HBx Protein 
The HBx protein is the smallest protein of the HBV with 154 amino 
acids and a molecular weight of ~17kDa.  It is a regulatory protein that 
promotes virus gene expression and replication by trans-activating the virus 
promoters and enhancers [33,129]. The sequence of HBx is well-conserved in 
other hepadnaviruses such as woodchuck hepatitis virus and ground squirrel 
hepatitis virus, except for the last 14 amino acids [130].  However, in avian 
hepadnaviruses, either no X protein or a highly divergent X protein is encoded 
[131,132].  Interestingly, only chronic infections with mammalian 
hepadnaviruses are associated with the development of HCC [133], strongly 
suggesting that HBx plays an important role in the development of HCC.  
Both full length (FL) and altered HBx proteins have been reported to be 
present in HCC samples. 
FL HBx has been widely implicated in hepatocarcinogenesis by 
transactivating other genes [134-136], modulating p53 functions [137,138], 
cell cycle progression [139,140], inhibition of DNA repair [141] and 
transformation of cultured cells [142,143].  In addition, FL HBx was reported 
to be able to induce HCC in certain lines of transgenic mice [144-146] but not 
others [147-150].  FL HBx also appears to be essential in initiating cccDNA-
driven transcription of the HBV RNAs [151].  Moreover, it also modulates the 
transcription of DNMT required for maintenance of hypomethylation of tumor 
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suppressor genes [152], promoting hypermethylation of these genes, thereby 
accelerating hepatocarcinogenesis. 
On the other hand, there are also evidences suggesting that FL HBx 
possesses tumor suppressive abilities.  It is frequently reported to be able to 
confer a pro-apoptotic potential to hepatocytes [153,154], inhibit clonal 
outgrowth of cells and induce apoptosis independent of p53 as well as a late 
G1 cell cycle block [155] and suppress focus formation induced by the 
cooperation of ras and myc oncogenes [156].  However, the pro-apoptosis 
function could be a compensatory effect for the increased cell proliferation 
rate caused by HBx resulting in an increased turnover rate of hepatocytes 
which facilitates accumulation of more mutations in the process.  
Interestingly, integration of the HBV into the host genome often leads 
to disruption of the 3’-end of the HBx gene, resulting in the production of 
HBx-host chimeric or truncated HBx protein [157].  These deletion mutants 
appear to lose the pro-apoptotic function possessed by the intact HBx, thus 
increasing the tendency to unregulated cell proliferation which enhances the 
transforming capacity of the protein [156]. 
1.2.6 Technological Advancement 
* This section is adapted from original research article, Soo Ting Toh, 
Yu Jin, Lizhen Liu, Jingbo Wang, Farbod Babrzadeh, Baback Gharizadeh, 
Mostafa Ronaghi, Han Chong Toh, Pierce Kah-Hoe Chow, Alexander Y-F 
Chung,  London L.-P- J Ooi, Caroline G-L Lee (2013).  Deep sequencing of 
the Hepatitis B Virus in Hepatocellular Carcinoma patients reveals enriched 
22 
integration events, structural alterations and sequence variations.  
Carcinogenesis, 34(4):787-98 by permission of Oxford University Press. 
The studies on HBV integration started as early as late 1970s.  As 
summarized in Table 1.2, the earliest methods used for characterization of 
HBV integration sites was Southern blotting by hybridizing labeled HBV 
probes with restriction enzyme digested DNA from HCC patients or cell lines.  
Some of these were coupled with phage libraries construction, cloning and 
subsequent Sanger or Maxam and Gilbert sequencing methods to determine 
the sequences at the viral-host junctions [92,117,120-122,158-172].  At that 
time, chromosomal location of integration sites were determined by in situ 
hybridization using probes derived from the adjacent host genomic sequences 
due to the unavailability of human genome sequence [173].  Therefore, with 
regards to the sites of HBV integration in the host genome, information 
obtained was limited at gross chromosomal rather than gene level.  In addition, 
the number of samples analyzed was also small primarily due to the labor-
intensive nature of the techniques used. 
As the polymerase chain reaction (PCR) techniques became more 
common in the early 1990s, Alu-PCR [105,107,111,174-178], inverse PCR 
(IPCR) [179,180], restriction site PCR (RS-PCR) [110] and cassette/adaptor-
ligation-mediated PCR [106,108,181,182] have been used to identify HBV 
integration sites in the host genome.  The localization of integration sites in the 
host genome has also become easier with the near-completion of the human 
genome sequence.  Since then, specific genes affected by HBV integration 
events were being reported in most of the studies.  However, as tumor 
progression is often associated with the rearrangement of both viral and 
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cellular sequences [91,183] as well as the frequent mutations in the HBV 
genome, the lack of a priori knowledge on the HBV sequences in each patient 
sample may lead to PCR failure and false negative results when the designed 
primers reside on deleted or polymorphic sites of HBV genome.  To increase 
the completeness of the methods, many PCR reactions and even bacterial 
cloning have to be carried out which make the process laborious and costly. 
Therefore, these methods restricted previous studies to characterize only the 
most common HBV integrant(s) in only a limited number of patients and 
hence the role of HBV integration in hepatocarcinogenesis remains uncertain 
and controversial.  Nonetheless, these small-scale isolated studies generally 
suggested that HBV integrates randomly in the host genome [91], or primarily 
into intronic or inter-genic regions [184], chromosomal fragile sites [95], 
scaffold/matrix attachment regions and repeat/satellite sequence rich region of 
the host genome [37]. 
To gain further understanding on the possible role of HBV integration 
in HCC, there is a need to develop an unbiased method that characterizes the 
whole spectrum of HBV integration sites within the host genome without 
having to perform loads of PCR and bacterial cloning which are laborious yet 
incomprehensive.  Fortunately, with the recent advances in the DNA 
sequencing technology, the integration sites of HBV in the genome of HCC 
may now be characterized in a more comprehensive manner using the second 
generation sequencers, allowing us to analyze the extent and functional impact 
of HBV integration in the host genome.   
Several second generation sequencing platforms are available currently.  
The selection of an appropriate sequencing platform for a particular 
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experiment is critical as it determines whether the sequencing results can be 
used to the maximum to answer biological questions.  In addition, it is also 
important to understand the imperfections in the sequencing data and how 
these pose challenges and cause biases in the downstream analysis.  Table 1.3 
summarizes the methods, throughputs, as well as the advantages and 
disadvantages of 4 major second generation sequencers compared to the first 
generation sequencers. As shown in Table 1.3, all the second generation 
sequencers can produce significantly higher throughput of sequencing data per 
run compared to the first generation sequencers.  In addition, the second 
generation sequencers can sequence large amounts of single-stranded DNA 
without the need of bacterial cloning.  The Roche/454 Genome Sequencer (GS) 
FLX platform is among the second generation sequencers that can offer the 
longest read lengths of around 400 bps using the Titanium reagents.  Figure 
1.8 shows the capability of the GS FLX sequencer to simultaneously sequence 
large amount of beads carrying clonally amplified DNA sequences. 
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Table 1.2: Summary of publications on HBV integration from 1980-2012 




1 PLC/PRF/5 cell line Southern blot NA NA [158] 






13 HCCs, 17 chronic 
hepatitis, 2 acute hepatitis 
Southern blot NA NA [92] 
4 
13 HCCs (8 HBsAg +ve, 5 
HBsAg -ve) + PLC/PRF/5 
cell line 
Southern blot NA NA [160] 
5 
3 short term (<2 years), 5 
long term (>8-10 years) 
carriers and 6 non-HBsAg 
carriers 
Southern blot NA NA [161] 
6 
3 integrated HBV DNA 
sequences cloned from 
PLC/PRF/5 









3 hepatoma cell lines, huH-
1, huH-2 and KG-55-T 
Southern blot NA NA [163] 
8 
2 HBsAg, HBeAg and anti-
HBcAg +ve patients' T and 
NT tissues 
Southern blot + 
Sanger 
sequencing 
NA DR1/DR2 [164] 
9 
4 clones of viral-human 
junctions from PLC/PRF/5 
cell line 









huH2-2 human hepatoma 
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Figure 1.8: Capability of FLX genome sequencer to sequence single clone 
without bacterial cloning.  Single-stranded DNA template carrying A and B 
linkers are annealed to excess DNA capture beads carrying either A or B 
oligos, depending on the sequencing direction.  At this step, titration assay was 
performed to ensure that only 1 starting effective fragment anneals to each 
bead.  Beads and PCR reagents are then emulsified in water-in-oil micro-
reactors followed by emulsion PCR where millions of clonally amplified 
sequencing templates are generated on each bead.  Micro-reactors are then 
broken to isolate DNA-containing beads.  DNA-positive beads are then 
enriched and loaded into PicoTiter Plate
TM
 for sequencing.  The size of the 
well ensures that only one bead will be loaded into each well to achieve 
clonality without bacterial cloning and colony picking. (Adapted from 
http://www.454.com/) 
 
As shown in Table 1.2, two recent studies reported ‘short-read’ whole 
genome paired-end deep sequencing of 4 and 88 HCC patients [112,113], 
respectively.  These two studies identified significantly more integration sites 
compared to the various previous publications owing to the ultra-high 
throughput capacity of the sequencing platforms used.  
In this study, we employ strategies to comprehensively enrich for DNA 
fragments containing HBV sequences in a generally unbiased manner from the 
complex genome of several HCC patients for sequencing using the Next-
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Generation GS-FLX-Sequencer (Roche).  Sequencing using the FLX System 
which is capable of long read lengths (400-600 bases), rather than other 
platforms with significantly shorter read lengths, will facilitate the accurate 
identification of integration sites and the discovery of novel rearrangements 
within a single read without paired-end sequencing or computational inference 
providing the confidence that the observed complex structural variations are 
less likely to be artefactual.  With the capability of the FLX system to 
sequence long DNA fragments, we are also able to analyze the structural 
alterations as well as sequence variations within the HBV genome. 
1.3 Aims of this Study 
Due to technological limitations, previous studies that characterized 
specific regions of the viral genome may present only a partial view of the 
genomic status of HBV in HCC samples.  Nonetheless, based on the findings 
from these studies, the genomic status of HBV appears to be complex in HCC 
samples.  Since HBV integration can disrupt host genes/deregulate host gene 
expression or a subset of mutated HBV proteins may play an important role in 
hepatocarcinogenesis, it is worthwhile to comprehensively characterize HBV 
in a large number of HCC patients.   
This study aims to describe and analyze the in-host complexity of 
HBV in tissues in which HCC develops as well as their adjacent non-tumor 
tissues in order to understand the possible role played by HBV in HCC.  
Characterization of the status of HBV in the adjacent non-tumor in addition to 
the tumor tissues of the same patient might provide clues to the molecular 
events closely preceding the development of HCC.  Departing from previous 
southern blot and PCR-based methods, we characterized 48 pairs of HCC 
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samples using an HBV DNA enrichment strategy using HBV-specific 
oligonucleotide probes that can capture a broad spectrum of HBV DNA 
species and integrants from the complex genome of HCC samples without 
gene-specific PCR.  The HBV-enriched DNA libraries were then sequenced 
using the recent state-of-the-art ultra-high-throughput GS-FLX sequencer.   
The specific aims of this study are: 
1. To characterize HBV integration sites in the host genome 
2. To characterize the structural alterations and sequence variations in the 
HBV genome 
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CHAPTER 2:  MATERIALS AND METHODS 
* This chapter is adapted from original research article, Soo Ting Toh, 
Yu Jin, Lizhen Liu, Jingbo Wang, Farbod Babrzadeh, Baback Gharizadeh, 
Mostafa Ronaghi, Han Chong Toh, Pierce Kah-Hoe Chow, Alexander Y-F 
Chung,  London L.-P- J Ooi, Caroline G-L Lee (2013).  Deep sequencing of 
the Hepatitis B Virus in Hepatocellular Carcinoma patients reveals enriched 
integration events, structural alterations and sequence variations.  
Carcinogenesis, 34(4):787-98 by permission of Oxford University Press. 
2.1 HCC Patient Samples 
The tissue samples used in this study were from anonymized HCC 
patients and had prior approval from the NCCS Institutional Review Board 
(NCC_IRB_No_2007/437/B).  The tissues were obtained from the National 
Cancer Centre of Singapore (NCCS) Tissue Repository which had obtained 
written informed consent from the study participants.  The demographic and 
clinicopathologic characteristics of the 144 HCC patients used in this study 
can be found in Appendix A.  The numbers of patient samples used for each 
experiment are indicated in Table 3.1. 
2.2 Extraction of Genomic DNA from HCC Patient Tissues 
To extract genomic DNA from patient tissues, 25mg of tissue sample 
was lysed overnight at 56˚C in 200μL of lysis buffer mixture [containing 
180μL of lysis buffer (Qiagen) and 20μL of proteinase K (Qiagen)].  Four 
microliters of 20mg/mL RNase A (Qiagen) was added and the sample was 
incubated at 37˚C for 10 minutes.  Equal volume of UltraPure™ 
Phenol:Chloroform:Isoamyl Alcohol (25:24:1, v/v) (Invitrogen) was then 
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added to the mixture which was vortexed for 15 seconds and centrifuged at 
13,000rpm for 10 minutes. The supernatant which contains DNA was 
transferred to a new tube and residual phenol was removed by an additional 
step of chloroform purification.  The DNA was then precipitated using ethanol, 
sodium acetate and glycogen before being re-dissolved in nuclease-free water 
(Ambion).  
2.3 Analyses of the Gross Structure of HBx Gene  
Primers encompassing the full length HBx (nt. 1-465) were first 
employed to determine which samples carried the full length HBx gene.  
Those samples in which full length HBx gene was not detected were then 
screened using primers encompassing the 5’-end of HBx (nt. 1-323) to 
determine if the HBx gene was deleted at the 3’-end.  Those samples for which 
no PCR product was obtained using both sets of primers were finally screened 
using primers encompassing the 3’-end of HBx (nt. 173-465) to determine if 
they carried HBx gene that was deleted at the 5’-end.  HBx was considered to 
be undetected in a sample if no PCR product was obtained using all the three 
sets of primers.  The locations and sequences of the primers used are shown in 









































































































































































































































































































































Figure 2.1: Locations (A) and sequences (B) of primers used for 
characterization of gross structure of HBx gene. 
 
2.4 Sequence Analyses of HBV DNA in HCC Patient Plasma 
Viral DNA was extracted from the plasma of HCC patients using the 
QIAamp MinElute Virus Spin Kit (Qiagen) according to the manufacturer’s 
instructions.  Eight different regions within the HBV genome were amplified 
and sequenced using the 8 sets of primers listed in Figure 2.2.  The PCR 
reactions were performed using the Platinum® Taq DNA polymerase high 
fidelity (Invitrogen) with the following condition: 94˚C for 2 minutes, 94˚C 
for 40 seconds, 59˚C for 30 seconds, 68˚C for 1 minute and 68˚C for 1 minute.  
Steps 2-4 were repeated 35 cycles.  The PCR products obtained were treated 
with EXOnuclease I (New England Biolabs) and shrimp alkaline phosphatase 
(SAP) (Promega) at a ratio of 1:10 for 1 hour at 37°C followed by inactivation 
of the enzymes at 80°C for 15 minutes. 
Sequencing was then performed using the ABI BigDye® Terminator 
(V3.1) Cycle Sequencing kit (Applied Biosystems).  Briefly, 1µL of the 
EXOSAP-treated PCR product was mixed with 0.3 pmol/µL of primer, 2.5µL 
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of BigDye® Terminator V3.1 sequencing buffer, 0.8µL of BigDye® 
Terminator V3.1 Mix (Applied Biosystems) and topped up with H2O to 10µl. 
The conditions for the cycle sequencing reactions are as follows: 30 cycles at 
96°C for 10 seconds, 50°C for 5 seconds and 60°C for 4 minutes.  The 
sequencing extension product was then purified using ethanol precipitation.  
Briefly, 1µL of 250mM EDTA, 1 µL of 20mg/mL glycogen and 40 µL of cold 
100% ethanol was added to the extension product.  The tube was then 
centrifuged at 13,000 rpm for 30 minutes at 4°C.  The precipitated DNA pellet 
was then washed once with 70µL of 70% ethanol and dried at 70°C for 3 
minutes.  The DNA pellet was then resuspended in 10µL of Hi-Di
TM
 
Formamide (Applied Biosystems) and resolved by automated capillary 





HBV_1F 5'-SCCATATCGTCAATCTTMTCG  
HBV_1R 5'-GAAGTCCACCACGAGTCTAG 
HBV_2F 5'-ACAAAACCTWCGGACGGAAA  
HBV_2R 5'-AAAGCCCTACGAACCACTGA 








HBV_7F 5'-GCTATGTCAAYGTTAATATGGGC  
HBV_7R 5'-AGGCGAGGGAGTTCTTCTTC 











Figure 2.2: Sequences and locations of 8 different sets primers used for 
amplification and sequencing of HBV DNA fragments. 
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2.5 Design of HBV Oligonucleotide Probes  
Since there are numerous different variants of HBV reported in NCBI 
GenBank, in order to facilitate the comprehensive enrichment of the different 
HBV sequences in HCC patients, ~70-mer HBV oligonucleotide probes were 
designed primarily within the conserved regions of 96 different HBV strains 
that are mainly of genotypes B and C which represent the most common 
strains found in Singapore.  To ensure exhaustive coverage of the HBV and to 
enrich for all HBV-related sequences whether it is intact or deleted, a total of 
26 oligonucleotide probes were designed to span the entire HBV genome at 
approximately 60 bps apart.  As such, some probes have to be designed within 
the less conserved or polymorphic regions of HBV. These probes were 
designed such that nucleotide from one genotype (either B or C) was used at 
every alternate polymorphic site to ensure that the probes can be used to 
capture HBV of either genotype (Figure 2.3A).  When a probe was designed in 
a highly polymorphic region (>10 polymorphic sites), two haplotypes of 
oligos were designed to capture both genotypes.  All the probes were 
biotinylated at the 3’-ends.  The locations and sequences of the 26 
oligonucleotide probes designed are shown in Figure 2.3B & C.  
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22 (a) 5'-TGCCTGCTAGGTTTTATCCCAATGTTACTAAATATTTGCCCTTAGATAAAGGGATCAAACCGTATTATCC- Biotin




26 5'-GGCCTGAGGATGAGTGTCTCTTAGAGGTGGAGATATGGGAGTAGGCTGCCTTCCTGACTGCCGATTGGTG- Biotin  
Figure 2.3: Design of HBV oligonucleotide probes. (A) An example to 
illustrate the design strategy for HBV oligonucleotide probes within 
polymorphic regions. (B) Distribution of the 26 probes on HBV genome. (C) 
Sequences of the 26 probes. 
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2.6 Pre-capture DNA Library Construction 
The pre-capture DNA library was generated by sonicating 15μg of 
genomic DNA to 0.4-1kb fragments using the Bioruptor® (Diagenode).  The 
ends of the fragmented DNA were repaired using End-It™ DNA end-repair kit 
(Epicentre Biotechnologies) to generate blunt-ended fragments.  The blunt-
ended DNA fragments were then ligated with linkers A (5’- 
CCATCTCATCCCTGCGTGTCTCCGACTCAG-6mer barcode) and B (5’-
CCTATCCCCTGTGTGCCTTGGCAGTCTCAG-6mer barcode) (synthesized 
by AITBiotech).  Each set of linkers A and B carry a unique 6-mer barcode 
sequence at the 3’-end of a 30-nucleotide sequence which serves as priming 
site for post-HBV capture library amplification.  Each of the samples was 
assigned a set of linkers A and B carrying a unique barcode.  Ligation of the 
linkers allowed pooling of samples for multiplex enrichment and sequencing.  
The gaps generated by the ligation of non-phosphorylated linkers to the 
fragments were repaired using the Bst DNA polymerase, large fragment (New 
England Biolabs).  The incorporation of a 6-mer barcode unique to each 
sample will facilitate the identification of each sample in the pool and the 
correlation of the sequences with clinical phenotypes of the samples  [193].  
The 6-mer barcodes used are listed in Figure 2.4. 
39 

















































5'-TGCAGA 24T 48T  
Figure 2.4: Sequences of 6-mer barcodes used. 
 
2.7 Enrichment of HBV DNA 
To enrich for HBV DNA, the DNA library was denatured at 95˚C and 
hybridized with 10pmol each the 26 HBV oligonucleotide probes (synthesized 
by AITBiotech) for 16 hours at 55˚C.  The hybridization buffer comprised 
35% formamide, 5×SSC, 0.1% SDS, 0.1mM DTT in a total volume of 350μL.  
The probe-bound DNA was then incubated with pre-treated streptavidin-
conjugated magnetic beads (Invitrogen) at 55˚C for 30 minutes.  The beads 
were pre-treated with 1mL of 4% I-Block buffer (Applied Biosystems) 
containing 0.5% SDS and 15ng/μL sonicated salmon sperm DNA (sssDNA) 
(Stratagene) for 50 minutes at room temperature before use.  Non-
specific/unbound DNA was removed by 5 washing steps: Step 1: 1×SSC with 
0.1% SDS, room temperature, 1 minute; Step 2: 1×SSC with 0.1% SDS, room 
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temperature, 10 minutes; Steps 3-4 (stringent washes): 0.1×SSC with 0.1% 
SDS, 50˚C, 10 minutes; Step 5: H2O, room temperature, 30 seconds.  The 
DNA which remained captured on the beads after these washing steps were 
eluted by heating at 85˚C for 10 minutes in H2O.  The HBV-enriched DNA of 
24 patients was then combined and amplified using primers specific to linker 
A and linker B.  The primer specific to linker B was 5’-biotinylated.  The PCR 
reactions were carried out using the Advantage 2 PCR Polymerase Mix 
(Clontech) with the following conditions: 95˚C for 1 minute, 95˚C for 40 
seconds, 62˚C for 30 seconds, 68˚C for 1 minute, and final extension at 68˚C 
for 1 minute.  The PCR products were then concentrated using SpeedVac Plus 
SC110A (Savant) and ran on an agarose gel.  Fragments with sizes ranged 
from 0.4 to 1kb were extracted and purified using GeneCleanIII kit (MP 
Biomedicals) according to the manufacturer’s instructions.  Finally, only 
single-stranded DNA fragments that were A/B flanked were selected using 
streptavidin-conjugated magnetic beads (Invitrogen).  The enrichment of HBV 
sequences in human samples will increase the ratio of HBV to background 
human sequences facilitating the pooling of several patient samples into a 
single sequencing run making it cost-effective.  
The gel photos showing the quality of genomic DNA extracted from 
the 48 patients as well as the sonicated DNA can be found in Appendix B and 
Appendix C, respectively. The process of pre-capture DNA library 
construction and HBV DNA enrichment is illustrated in Figure 2.5A.  Two 
stringent washes were performed because more HBV DNA but similarly 
low/undetected amount of non-specific DNA was retrieved when compared 
with three stringent washes (Figure 2.5B).  As evident in Figure 2.5C, the 
41 
HBV DNA enriched was captured specifically by the HBV oligos as a control 
experiment without addition of oligos retrieved negligible amount of DNA.  
Integrated 
HBV Fragmentation 





























































































































Figure 2.5: Optimization of pre-capture DNA library construction and 
HBV DNA enrichment.  (A) Workflow of pre-capture DNA library 
construction and HBV DNA enrichment.  (B) Optimization of number of 
stringent washes performed.  (C) Assessment of extent of HBV DNA non-
specifically pulled down by magnetic beads. The optimization experiments in 
(B) and (C) were performed using single HCC sample.  The input DNA is the 
sonicated DNA from the same sample without undergoing the pre-capture 
DNA library construction and HBV DNA enrichment.  The DNA was 
quantitated using real time PCR measuring SYBR green.  Relative fold of 
enrichment was calculated using the 2
-(ΔCt)
 method (ΔCt = Ct after enrichment 
– Ct input). 
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2.8 Quality Assessment of HBV-enriched DNA Library  
The HBV-enriched single-stranded DNA fragment size distributions 
were assessed using the RNA 6000 Pico kit (Agilent) on a Bioanalyzer 2100 
(Agilent) according to the manufacturer’s instructions.  As shown in Figure 
2.6, majority of the single-stranded DNA fragments are between 0.4-0.8 kb in 
size. 
Enrichment specificity was evaluated by quantitative real time PCR 
measuring SYBR green fluorescence using the 7500 Real Time PCR system 
(Applied Biosystems) according to the manufacturer’s instructions.  Four sets 
of HBV primers and four sets of human gene primers which are highly 
homologous to the HBV genome were designed to quantitate the abundance of 
the HBV (target) and highly homologous human (non-target) DNA 
respectively in the DNA libraries before and after HBV enrichment for 3 
randomly selected patients using qPCR.  Same amount of DNA (250pg) were 
added as template for the DNA libraries before and after enrichment.  Relative 
fold of enrichment was calculated using the 2
-(ΔCt)
 method (ΔCt = Ct after 











Figure 2.6: Size distribution of single-stranded DNA fragment libraries.  
Majority of the DNA fragments are between 0.4-0.8 kb.  M: Marker; S: 
Sample. 
 
2.9 GS-FLX Titanium Sequencing 
2.9.1 Emulsion PCR (emPCR) 
The HBV-enriched A/B flanked single-stranded DNA (ssDNA) 
libraries were quantified by fluorometry using the Quant-iT™ RiboGreen® 
RNA Assay Kit (Invitrogen).  The assay was carried out in duplicate for each 
ssDNA library as well as standard curve.  The concentration of each ssDNA 
library was calculated and emulsion PCR (emPCR) was performed using the 
GS emPCR Kit (Roche) according to the manufacturer’s instructions.  Briefly, 
the ssDNA was immobilized onto DNA capture beads and added to a mixture 
of amplification mix and oil and vigorously shaken on a tissue lyser (Qiagen) 
to create “micro-reactors”.  Emulsion was dispatched in a 96 well plate and the 
PCR amplification was performed according to the manufacturer’s 
recommendations.  After the emPCR, the emulsion was broken, and the beads 
carrying the amplified DNA libraries were recovered.  Positive beads were 
purified by binding of the biotinylated primers to streptavidin-coated magnetic 
beads.  Next, the DNA library beads were separated from the magnetic beads 
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by denaturation of the PCR products, leaving a population of bead-bound 
ssDNA fragments.  Then, sequencing primer was annealed to the amplified 
ssDNA and the number of beads carrying amplified ssDNA was evaluated 
using a Z2™ Cell Counter (Beckman Coulter).  
2.9.2 Titanium Sequencing 
The ssDNA libraries were sequenced using the 70 x 75mm Titanium 
Pico-Titer plate device (Roche) and the XLR-70 sequencing kit (Roche).  
Briefly, the 70 x 75mm Pico-Titer plate was divided into two regions using the 
Large Regions Bead Loading Gasket (Roche).  Two million DNA beads were 
loaded per region according to the manufacturer’s recommendations, followed 
by the appropriate volume of packing beads and enzyme beads.  After the pre-
wash run, the sequencing run was launched with the “Full Analysis for 
Shotgun” parameter set.  
2.10 Analysis of FLX Sequencing Data 
As shown in Figure 2.7, sequence reads obtained from FLX 
sequencing were assigned to each patient sample based on the unique 6-mer 
identification barcodes.  The assigned reads were then searched against the 
human genome (NCBI reference contig assembly Build37) using the NCBI 
standalone software tool BLASTN 2.2.23+ [194].  Reads that were fully 
matched to human genome were removed.  Reads that were fully matched to 
human genome were defined based on two criteria: 1) the matching identity of 
the local alignment between sequence read and human genome was above 
80%; 2) the unmatched sequences at the two ends of the sequence read were 
<10bps. The remaining reads were further searched against HBV genome 
sequences downloaded from the NCBI Genome database and those with no 
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match to HBV genome were removed.  Reads that were not filtered out 
represent reads that potentially contain HBV sequences.  These reads were 
then assembled into contigs using the de novo assembly algorithm from 
DNAStar SeqMan NGen®.  DNAStar Lasergene® Core Suite was used for 
the visualization of assembled contigs.  The assembled contigs and some 
unassembled reads were then searched against HBV and human genome for 
sequence identities.  Those contigs/reads that were either fully matched to 
HBV genome or containing HBV sequence hits of ≥52bps were considered as 
high confidence HBV-containing contigs/reads and were used for further 
analysis.  Fifty-two base pair length was set as a threshold because the 
sequence similarity between HBV genome and human genome was largely 
below 52bps.  Thus, sequences which have more than 52bps that are matched 
to the HBV genome were considered as high confidence HBV reads.  These 
HBV-containing contigs/reads included those containing solely HBV 
sequences as well as those containing both HBV and human sequences within 
the same contigs/reads.  Structural alterations in HBV genome were identified 
from the pure HBV sequences carrying deletions, inversions or duplications.  
The HBV integration sites in the human genome were determined from the 
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Figure 2.7: Sequencing data analysis workflow.  (Reprinted by permission 
from Oxford University Press. Carcinogenesis. Toh et al., 2013; 34(4):787-98.) 
 
2.11 Evaluation of the Existence of Preferred Region within Viral or 
Human Genome for Integration 
The following method was employed to assess whether there was 
statistically significant enrichment of specific regions in the HBV genome or 
specific human chromosomes as favored sites for integration.  Based on the 
number of integrated sites observed in the FLX sequencing, the same number 
47 
of sites was randomly generated in silico from the human or HBV genome.  
The chromosome or a region (nucleotide 1600-1900) in HBV genome that 
these randomly generated integration sites reside was noted.  The above 
process was repeated 1,000,000 times to generate an empirical distribution of 
number of integration sites for each human chromosome or the region of 
interest in the HBV genome. A chromosome or the region of interest in HBV 
genome was considered as significantly enriched for HBV-host integration if 
the observed number of integration in FLX sequencing was higher than the 
99th percentile of the empirical distribution generated from the random 
sampling.  The random sampling and the probability calculations were 
performed using the R Project for Statistical Computing.  Similar approach 
was used to evaluate if there was enrichment of integration sites in the 
different functional regions of the human genome.  Genic region was defined 
as the combination of promoters (5kb upstream of TSS), exons (including 
3’UTR) and introns.  
2.12 Analyses of Potential Consequences of HBV Integrations into the 
Host Genome  
For integrations that occurred within coding regions, in silico 
translation tool was used to determine whether a truncated or a chimeric 
protein was produced.  For viral integrations that occurred in promoters (5 kb 
upstream the transcription start site (TSS)), exons or in introns within 400 bps 
from the nearest intron/exon boundaries of known genes, the resulted viral-
host contig sequences were scanned for regulatory element binding sites 
(REBS).  These REBS including transcription factor binding sites (TFBS), 
exonic splicing enhancers (ESE), exonic splicing silencers (ESS) and intronic 
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splicing regulatory elements (ISRE) were analyzed using a toolkit developed 
in our laboratory.  This toolkit utilizes TRANSFAC Gene Transcription Factor 
database (http://www.biobase-international.com/pages/index.php?id=transfac) 
(version 2011.3) to identify possible TFBS and ESE/ESS/ISRE motif 
signatures were extracted from various publications [195-199].  Sequences 
200 bps up- and down-stream of the integration sites (flanking sequences) 
were also extracted from the human reference genome and the same scanning 
was performed.  REBS that were predicted to be present in the flanking 
sequences but not in the viral-host contig sequences represent those that were 
disrupted by HBV integration.  Viral-host contigs resulted from viral 
integrations in the 3’-UTR were scanned for disruption of predicted miRNA 
binding sites available in mirRanda database [200].  
2.13 PCR for Validation of in silico-inferred Contigs from Deep 
Sequencing 
In silico-inferred contigs were validated through PCR using primers 
designed at the extreme ends of the contig sequences or immediately before 
repeat region of the extreme end followed by Sanger Sequencing.  The PCR 
reactions were carried out using either the PfuUltra hotstart DNA polymerase 
(Stratagene) or Platinum® Taq DNA polymerase high fidelity (Invitrogen).  
For PfuUltra hotstart DNA polymerase (Stratagene), the reaction condition 
was as follows: 95˚C for 2 minutes, 95˚C for 30 seconds, 50-60˚C for 30 
seconds, 72˚C for 1-6 minutes and 72˚C for 10 minutes.  For Platinum® Taq 
DNA polymerase high fidelity (Invitrogen), the reaction condition was as 
follows: 94˚C for 1 minute, 94˚C for 30 seconds, 50-60˚C for 30 seconds, 
68˚C for 1-6 minutes and 68˚C for 5 minutes.  The annealing and extension 
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temperatures were variable depending on the specific primer sequences and 
the lengths of amplicons respectively.  
2.14 Viral-host Chimeric Transcripts 
Expression of viral-host chimeric transcripts was evaluated through 
reverse transcription (RT) PCR using the same sets of primers used for 
validation of in silico-inferred contigs from deep sequencing. 
2.15 Extraction of Total RNA from HCC Patients and Reverse 
Transcription  
The patient tissues were homogenized in buffer RLT (Qiagen) 
containing 1% β-mercaptoethanol using the gentleMACS dissociator (Miltenyi 
Biotec).  Total RNA was extracted using the RNeasy Mini Kit (Qiagen) 
according to the manufacturer’s instructions.  One microgram of total RNA 
was treated with RQ1 DNase (Promega) according to the manufacturer’s 
instructions to remove genomic DNA contamination.  The RQ DNase-treated 
RNA was then reverse-transcribed using SuperScript™ II reverse transcriptase 
(Invitrogen) and Anchor 3 primer (5’-
GGCCACGCGTCGACTAGTACTTTTTTTTTTTTTTTTT) according to the 
manufacturer’s instructions.  PCR was then performed as described above.  
2.16 5’ Rapid Amplification of cDNA Ends (5’-RACE)  
Selection and generation of full length cDNA was performed using the 
FirstChoice® RLM-RACE kit (Ambion) according to the manufacturer’s 
instructions.  As per manufacturer’s instructions, a linker was ligated to the 
decapped full length mRNA before the cDNA was generated using 
SuperScript™ III reverse transcriptase (Invitrogen) instead of the reverse 
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transcriptase from the kit.  An initial PCR was performed using a primer that 
was specific to that linker and a primer that resided on the human part of the 
chimeric transcript.  A subsequent nested PCR was then performed using a 
different linker primer that was 3’ to the 1st linker primer and another primer 
located within the viral region of the chimeric transcript.  The nested PCR 
product was then sequenced using Sanger sequencing.  
2.17 3’ Rapid Amplification of cDNA Ends (3’-RACE)  
The cDNA generated was first amplified using a primer that was 
specific to the viral part of the chimeric transcript and the AUAP primer (5’- 
GGCCACGCGTCGACTAGTAC) which was designed based on the adaptor 
sequence that was incorporated in the Anchor 3 primer used for reverse 
transcription.  A nested PCR was performed using another primer that resided 
on the human part of the chimeric transcript and the AUAP primer.  For the 23 
patients that 3’ ends of HBx transcripts were analyzed, as the sequences fused 
to 3’ end of HBx were unknown, the 3’-RACE was carried out using similar 
approach except that for both the initial and nested PCR, the gene specific 
primers used were specific to HBx. The primer used for the first PCR was 
specific to nucleotide 54-73 of HBx gene (pHBxIF1: 5’- 
ACGTCCCGTCGGCGCTGAAT) and the primer used for the nested PCR 
was specific to nucleotide 173-191 of HBx gene (HBxF1: 5’-
TCCCCGTCTGTGCCTTCTC).  The nested PCR product was cloned into the 
pGEM®-T Vector (Promega) followed by bacterial transformation.  Colony 
PCR was performed to screen for positive clones.  Positive clones of different 
sizes representing variable 3’-ends of HBx transcripts were sequenced.  
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2.18 Cloning 
HBx-host chimeric protein open reading frames (ORFs) were predicted 
using Vector NTI Advance® 10 (Invitrogen).  The predicted chimeric protein 
ORF together with the full length HBx gene from pEco63 (ATCC) were 
cloned into the Vivid Colors™ pcDNA™6.2/EmGFP-Bsd/V5-DEST 
mammalian expression vector (Invitrogen) using the pENTR™ Directional 
TOPO® Cloning Kit (Invitrogen) and the Gateway LR Clonase™ II enzyme 
mix (Invitrogen) as well as the pAdenoX-ZsGreen1 adenoviral vector 
(Clontech) using the In-Fusion® HD Cloning Kit (Clontech) according to the 
manufacturers’ instructions.  The vector map can be found in Appendix D.  
All the chimeric and full length HBx protein ORFs were N-terminal tagged 
with the FLAG (N-DYKDDDDK-C) sequence.  The pcDNA™6.2/EmGFP-
Bsd/V5-GW/CAT and pAdenoX-ZsGreen1 carrying a short random sequence 
were used as the negative controls for transfection and transduction 
experiments, respectively.  The primers used for amplifying the mutant and 
full length HBx ORFs for cloning into the Vivid Colors™ 
pcDNA™6.2/EmGFP-Bsd/V5-DEST mammalian expression vector  and 
























Figure 2.8: Sequences of primers used for amplifying the full length and 
mutant HBx ORFs for cloning into the Vivid Colors™ pcDNA™ 
6.2/EmGFP-Bsd/V5-DEST mammalian expression vector (A) and 
pAdenoX-ZsGreen1 adenoviral vector (B). 
 
2.19 Cell Culture 
Huh-7, HEK293 and HepG2 cells (ATCC) were maintained at 37 °C in 
a humidified atmosphere of 5% CO2 in Dulbecco's Modified Eagle's Medium 
(DMEM) supplemented with 10% fetal calf serum.  
2.20 Transfection 
Huh-7 cells were seeded onto 6-well plates and grown to 70-80% 
confluency.  Transfections of chimeric proteins, the FL HBx and the control 
constructs were performed using Lipofectamine™ 2000 Transfection Reagent 
(Invitrogen) according to the manufacturer’s instructions.  Sixteen hours after 
transfection, the medium was replaced with fresh DMEM.  Cells were 
observed under a fluorescence microscope to detect Emerald Green 
Fluorescent Protein (EmGFP) fluorescence to assess transfection efficiency. 
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2.21 Colony Formation Assay 
Huh7 cells transfected with each of the 5 mutant HBx, FL HBx and 
control (carrying CAT gene) constructs were subcultured at a ratio of 1:100, 24 
hours after transfection.  The cells were cultured in Blasticidin (Invitrogen 
Life Technologies) selective medium for 3 weeks (4.5µg/ml and 1.5µg/ml for 
biological replicates 1 and 2, respectively).  Drug-resistant colonies were fixed 
with 4% formaldehyde for 30 minutes at room temperature, followed by 
staining with 0.5% methylene blue in 50% methanol for 2 hours and scoring of 
the colonies. 
2.22 Western Blot Analyses 
Transfected cells were treated with proteasome inhibitor, MG-132 
(Calbiochem) for 6 hours prior to cell harvesting. 5×10
5
 cells were harvested 
and resuspended in 30μL of RadioImmunoPrecipitation Assay (RIPA) buffer 
(Tris 50mM, NaCl 150 mM, SDS 0.1 %, Sodium Deoxycholate 0.5 % and 
NP40 1%) containing Complete
TM
 Protease Inhibitor Cocktail (Roche).  The 
cells were kept at 4˚C for 15 minutes before being sonicated using the 
Bioruptor® (Diagenode) at the ‘High’ frequency setting for a total of 10 
minutes with 30 seconds intervals after each sonication of 30 seconds.  The 
sonicated lysate was then centrifuged at 13,000 rpm for 20 minutes at 4˚C and 
the supernatant solution was collected.  For protein isolation from HCC tissues, 
200μL of protease inhibitor-containing lysis buffer from the 
Immunoprecipitation kit (Protein G) (Roche Applied Science) was used to lyse 
a 3mm×3mm×3mm liver tissue.  The protein was released by sonicating the 
tissue using the Bioruptor® (Diagenode) at the ‘Low’ frequency setting for a 
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total of 10 minutes with 1 minute intervals after each sonication of 1 minute 
followed by centrifugation at 13,000 rpm for 10 minutes.  
Twenty micrograms (40μg for protein isolated from patient samples) 
of the protein lysate was mixed with loading buffer, heated at 99°C for 15 
minutes, then put on ice before being loaded onto a 15% PAGE gel and 
electrophoresed at 100V for 2 hours.  The size-separated proteins were then 
transferred from the gel onto PVDF membrane (Bio-Rad) at 100V for 2 hours 
at 4°C.  After transfer, the PVDF membrane was blocked with 2% ECL™ 
Advance Blocking Reagent (GE Healthcare) for one hour and incubated with 
0.2μg/mL rabbit anti-HBx polyclonal antibody, generated in the laboratory 
[201] for another hour.  The membrane was then washed 3 times with 
Phosphate Buffered Saline with 0.1% Tween 20 (PBST) for a total of 10 
minutes followed by incubation with a HRP-conjugated goat anti-rabbit 
antibody (Pierce) at 1:20,000 dilution for 50 minutes.  The membrane was 
then washed 5 times with PBST for 15 minutes each, followed by 
visualization using the Amersham ECL™ Advance Western Blotting 
Detection Kit (GE Healthcare). 
To evaluate the expression level of HBx protein in HCC patient 
samples, the intensities of the HBx protein bands were quantified using the 
AlphaImager 2000 and normalized against those of beta-actin of the same 
samples.  The relative fold change of HBx was calculated as the ratio between 
the normalized HBx expression in tumor and non-tumor samples.  A fold 
change of >1.5 between the tumor and non-tumor samples is considered as 
differential expression. 
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2.23 Production of Recombinant Adenovirus Carrying Mutant and Full 
Length HBx Genes 
Two microliters of the In-Fusion reaction mixture was used to 
transform 50μL of Stellar™ Competent Cells (Clontech) according to the 
manufacturer’s instructions.  Bacterial cells carrying positive clones verified 
by sequencing were subsequently amplified and plasmids were purified using 
the NucleoBond Xtra Plasmid Midi Kit (Macherey-Nagel) according to the 
manufacturer’s instructions.  The purified plasmids were then linearized using 
the PacI Restriction Enzyme (New England Biolabs) and transfected into the 
Adenovirus-packaging HEK 293 cells using the CalPhos Mammalian 
Transfection Kit (Clontech) according to the manufacturers’ instructions.  
When cytopathic effects were observed, the recombinant viruses were 
harvested by subjecting the HEK 293 cells to three consecutive freeze-thaw 
cycles in liquid nitrogen and 37°C water bath.  For preparation of high-titer 
virus stocks, the recombinant viruses were used to infect larger cultures (T175 
flasks) and viruses were harvested when cytopathic effects were observed.  
2.24 Recombinant Adenovirus Titration and Optimization of 
Transduction 
2.24.1 Virus Titration 
HEK293 cells were seeded into 24 well plates and grown to 40% 
confluency.  The different recombinant virus stocks were serially diluted at 




.  Five-hundred microliters (0.5 mL) of each of 
the serially diluted virus stocks were used to transduce the HEK293 cells in 3 
independent wells for each dilution.  Forty-eight hours post-transduction, the 
numbers of green fluorescent cells were counted from the wells transduced 
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 as the number of green fluorescent 







dilutions respectively).  The titer of the virus (ifu/mL) was calculated by the 






 dilutions were taken as the titer of the virus stock. 




2.24.2 Virus Transduction Optimization 
HepG2 cells were seeded into 6-well plates and grown to 60% 
confluency.  Appropriately titrated viruses carrying the different mutant and 
full length HBx were used to transduce HepG2 cells at multiplicity of 
infection (MOI) of 0, 100, 150, 200, 300 and 400.  Western blot analyses with 
specific rabbit anti-HBx and rabbit-anti-GAPDH (Santa Cruz) antibodies were 
used to assess the expression of HBx and GAPDH in the transduced cells.  
MOI of 150, 150, 200, 400 and 125 were chosen for the mutants from P1T, 
P2T, P9NT, P9T and full length HBx as they gave significant and similar HBx 
expressions across all constructs (Figure 2.9B).  MOI of 150 was chosen for 
the control vector without HBx based on >90% transduction efficiency with 
minimal cytotoxicity similar to all the HBx constructs (Figure 2.9A). 
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P1T  MOI: 150 P2T  MOI: 150 P9NT  MOI: 200 P9T  MOI: 400
FL  MOI: 125 Control  MOI: 150 UNINFECTED
A




Figure 2.9: Adenovirus transduction efficiency and HBx protein 
expression.  (A) Composite image of HepG2 cells showing high transduction 
efficiency of adenovirus carrying different HBx and control constructs at 
various MOIs indicated with minimal cytotoxicity.  (B) Western blot analyses 
of HBx and GAPDH in HepG2 cells transduced with viruses carrying the 
various HBx and control constructs. 
 
2.25 Preparation of RNA Samples for Whole Genome Expression 
Array 
HepG2 cells were transduced with adenoviruses carrying the different 
mutant and FL HBx as well as the control constructs at the corresponding 
MOI that gave rise to similar HBx expression across the different HBx 
constructs.  Forty-eight hours post-transduction, the cells were treated with 
proteasome inhibitor, MG-132 (Calbiochem) for 6 hours prior to cell 
harvesting.  Total RNA was extracted using the RNeasy Mini Kit (Qiagen) 
according to the manufacturer’s instructions.  One microgram of total RNA 
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was subjected to whole genome expression profiling using the Human HT-12 
v4 Expression Arrays (Illumina). 
2.26 Analysis of Sequence Variation within HBV Genome 
All contigs or unassembled HBV reads of genotypes B/C were 
compared with the respective consensus reference sequences to assess the 
sequence variation of HBV genome in the HCC patients.  Variation at the 
amino acid level of the four major HBV proteins (Polymerase, Large S, 
Precore/Core and X) was assessed by in silico translation of the DNA 
sequences. 
A consensus reference sequence for HBV of each genotype was 
generated by aligning 60 HBV sequences obtained from NCBI.  A nucleotide 
different from the reference sequence at a particular position was defined as 
“variant” and the percentage of variants at each nucleotide position was 
calculated by:  
Total number of contigs or reads carrying 
a specific variant 
Total number of contigs or reads 
covering that nucleotide position
 100% 
 
The HBV-containing contigs or unassembled reads were translated in 
silico to predict the effect of nucleotide variations on the four major HBV 
protein sequences (Polymerase, Large S, Precore/Core and X proteins).  As 
some of the contigs/unassembled reads might not include the entire protein 
ORF sequences, the following rules applied during the in silico translation. 
First, when the start codon of a protein ORF was not observed due to 
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truncation during integration into the host genome (i.e. the 5’-end of the viral 
protein ORF sequence was fused with a human sequence), the viral protein 
was not in silico translated.  In the cases when the start codon was not 
observed but no human sequence was detected at the 5’-end of the incomplete 
ORF, it was assumed that the start codon was present and the available DNA 
sequence was in silico translated based on the correct frame of the particular 
viral protein.  Second, when the 3’-end of a protein ORF was fused to a human 
sequence, the translation was performed according to the frame of the viral 
protein extending into the human sequence until the end of the DNA sequence 
or a stop codon was found, whichever was earlier. 
During the analysis of single amino acid substitutions, residues 
predicted from human sequences or as a result of frameshift due to insertions 
or deletions were excluded.  Hence, only high confidence substitutions were 
included.  A specific site in the amino acid sequences was considered as a 
variable site (or hotspot) when at least 10% (or 20%) of the samples carried a 
residue different from the reference sequence at that particular site.  The 
proportion of conservative (or non-conservative) substitutions was calculated 
by:  
Number of sites with conservative 
(or non-conservative) substitutions 




The proportions of variable sites (or hotspots) in the HBV proteins 
were calculated by: 
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Number of variable sites (or hotspots) 




CHAPTER 3: RESULTS 
* This chapter is adapted from original research article, Soo Ting Toh, 
Yu Jin, Lizhen Liu, Jingbo Wang, Farbod Babrzadeh, Baback Gharizadeh, 
Mostafa Ronaghi, Han Chong Toh, Pierce Kah-Hoe Chow, Alexander Y-F 
Chung,  London L.-P- J Ooi, Caroline G-L Lee (2013).  Deep sequencing of 
the Hepatitis B Virus in Hepatocellular Carcinoma patients reveals enriched 
integration events, structural alterations and sequence variations.  
Carcinogenesis, 34(4):787-98 by permission of Oxford University Press, with 
additional unpublished data presented. 
Table 3.1: Overview of Thesis 
Aspect # Pts Technique Objective Findings 
HBx 
49 PCR 
To characterize the 
gross structure of 
HBx gene 
3'-end of HBx is often not 






To characterize the 
sequences of HBx 
gene 
In 6/9 patients, the HBx 
sequences between the 
non-tumor and tumor 
samples are different 
In 4 of the patients, >1 
sequence variant of HBx 
are present in either the 
non-tumor or tumor 
samples 
HBV 15 
To characterize the 
genotypes of HBV 
in HCC patients' 
plasma 
Subgenotype B2 (Ba) and 
C2 (Ce) are the two most 
commonly observed HBV 







To assess if there 
is  enrichment of 
HBV integrations 
into any functional 
region within the 
host genome 
Significant enrichment of 
HBV integrations in the 
promoter region in tumors 
(P<0.001) 
HBV integrations are 
predicted to disrupt host 
gene regulatory element 
binding sites (REBS) 
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promoters, exons and 
introns) integrations are 
significantly correlated 
with gene expression 
compared to intergenic 
integrations (P<0.05) 
To assess if there 





integrate into chromosome 
10 in the tumors 
Integration into 
chromosome 10 is 
correlated with poorly 
differentiated tumors 
To assess if the 
genes affected by 
HBV integration 
are enriched in 
specific pathways 
Genes affected by HBV 
integration in the tumor 
samples are significantly 
categorized under cell 
cycle, cell death and 
survival, DNA replication, 
recombination and repair 
while most of those in the 
non-tumor samples are 
categorized under cellular 
function and maintenance 
and cellular assembly and 
organization. 
HBV 
To assess if there 
is any preferential 




enrichment of integration 
events were observed 
within nucleotides 1600-
1900 around the 3’-end of 
the HBx and 5’-end of the 
Precore/Core genes in 
both tumor (P < 0.001) 
and non-tumor (P < 0.001) 
samples 




The preferential region 
within HBV genome 
involved in integration 
was also statistically 
enriched for structural 
alterations in both non-
tumor (P < 0.001) and 
tumor (P < 0.001) samples 
10 RT-PCR 




transcripts are expressed 
only when integrations 
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transcripts can be 
produced as a 
result of HBV 
integration 
occur at the 3’-end of 




To characterize the 
3'-end of HBx 
transcripts 
Majority of HBx 
transcripts observed are 
HBx-host chimeric 
transcripts (tX-H) 
followed by truncated 
HBx (tX), then full-length 
(FL) HBx transcripts with 
HBx fused to other HBV 














The HBx-host chimeric 
proteins can be expressed 





To assess the 
colony formation 
ability of HBx-
host chimeric and 
full length HBx 
proteins 
C-terminal truncations in 
the HBx-host chimeric 
proteins abrogate the 
growth suppressive ability 




To assess the HBx 
protein expression 
in HCC patient 
samples 
HBx protein is over-
expressed in the tumor 
compared to adjacent non-









To examine the 
gene expression 
profiles of HepG2 
cells expressing 
mutant and FL 
HBx proteins 
The differentially 
expressed genes between 
mutant and FL  HBx 
protein expressing cells 
are primarily categorized 
under cellular growth and 
proliferation as well as 







To assess the 
extent of sequence 
variations within 
HBV genome 
Variations in the HBV 
genome are predicted to 
preferentially cause non-
conservative amino acid 
substitutions in HBV of 
genotype C, especially in 
the HBx 
# Pts: Number of patients examined 
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3.1 The Gross Structure and Sequence of HBx Gene 
3.1.1 The 3’-end of HBx Gene is often not Intact 
Before the availability of the next generation sequencing, we started 
the project by examining the gross structure of HBx, the smallest HBV gene in 
the tumor and adjacent non-tumor samples of 49 HCC patients, using a PCR-
based approach.  PCR screening of the 49 pairs of samples was performed 
sequentially using primers set I, II and III (Figure 3.1A) to examine which 
samples carry FL HBx (I) , 3’-end deleted but not FL HBx (II) and 5’-end 
deleted but not FL or 3’-end deleted HBx (III).  As shown in Figure 3.1B, we 
found that some forms of HBx DNA either FL, or 3’-deleted ones are present 
in 45/49 (91.8%) patients examined.  In 12/49 (24.5%) patients, the entire (FL) 
HBx could be amplified in both tumor and non-tumor samples.  However, in 
27/49 (55.1%) patients, only the 3’-end deleted but not the FL HBx can be 
amplified from either the non-tumor or tumor or both samples.  Interestingly, in 
15/49 (30.6%) patients, only the 3’-end deleted HBx but not the FL HBx can be 
amplified in the tumor samples while FL HBx can be amplified in the non-tumor 
samples.  These data suggest that in a significant proportion of HCC patients, the 
3’-end of HBx gene may not be intact in either the non-tumor or tumor samples 
and this phenomenon is more commonly observed in the tumor samples.  The 









































































































































































































































































































































I I 12 24.5%
I II 15 30.6%
II I 4 8.2%
II II 8 16.3%
I 0 3 6.1%
II 0 2 4.1%
0 I 0 0.0%
0 II 1 2.0%
0 0 4 8.2% 4 8.2%







Figure 3.1: The status of HBx gene in HCC patient samples. (A) 
Representative figures showing PCR products obtained using primers HBxF 
and HBxR (I), HBxF and HBxR1 (II) and HBxF1 and HBxR (III). NC: 
Negative control; PC: Positive control (pEco63). (B) The number of patient 
samples that carry either amplicon I, II or no amplicon.  N: Adjacent non-
tumor; T: Tumor; # of pt.: Number of patients; I: Amplicon I is present; II: 
Amplicon II is present while amplicon I is not; 0: No amplicon present. All 
samples which were negative for amplicons I and II also tested negative for 




3.1.2 Sequences of HBx are Different between Non-tumor and Tumor 
Samples 
From the characterization of the gross structure of HBx gene, 12 
patients were found to carry FL HBx in both the non-tumor and tumor samples 
(Figure 3.1B).  To examine the nucleotide sequences of HBx gene in HCC 
patients, we selected 9/12 patients for DNA sequencing analysis.  The DNA 
sequences were then in silico translated to obtain the amino acid sequences.  
As shown in Figure 3.2A, in 6/9 patients, the predicted HBx amino acid 
sequences between the non-tumor and tumor samples are different.  
Interestingly, in 4 of the patients, more than one sequence variants of HBx are 
present in either the non-tumor or tumor samples.  The FL HBx PCR 
amplicons are shown in Figure 3.2B.  Since even in the smallest gene of HBV, 
the HBx, there are sequence differences between the non-tumor and tumor 
samples and presence of different HBx sequence variants even within the 
same samples, it may be interesting to characterize the entire HBV genome in 
more patients in order to understand the extent of sequence or structural 
variations within the HBV genome.  This brings us to the main objective of 
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Figure 3.2: Analysis of full length HBx sequences. (A) Comparison of HBx 
amino acid sequences deduced from HBx DNA sequences. (B) Gel photo 
showing the amplification products of the full length HBx gene.  PC: Positive 
control (pEco63); N: Non-tumor; T: Tumor.  
 
3.2 HBV of Subgenotypes B2 and C2 are most Commonly Observed in 
Singaporean HCC Patients 
We first examined the sequences of HBV DNA extracted from the 
plasma of 15 HCC patients to determine the prevalence of HBV 
genotypes/subgenotypes in these patients.  Eight regions that collectively 
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cover most parts of the HBV genome were amplified and sequenced.  The 
sequencing data revealed that the patients examined were infected by HBV of 
either genotypes B (46.7%) or C (53.3%) with subgenotypes B2 (40.0%) and 
C2 (33.3%) being the most commonly observed subtypes that infect HCC 
patients in Singapore (Figure 3.3).  Within patients infected with HBV of 
genotype C, co-infection of both subgenotypes C1 and C2 were also observed 
in about 13.3% of patients (Figure 3.3).  This piece of data confirmed that the 









Mixed C1 & C2
 
Figure 3.3: Proportions of HBV genotypes/subgenotypes identified in the 
plasma samples of 15 HCC patients.  Subgenotypes B2 (Ba) and C2 (Ce) are 
most commonly observed in HCC patients in Singapore. 
 
To characterize the HBV genome in HCC tissues, we employed a 
strategy to capture the HBV DNA from the complex genome of HCC patients 
using HBV oligonucleotide probes before performing high-throughput 
sequencing on the HBV-enriched DNA.  Based on the finding that genotypes 
B and C are the two most prevalent genotypes in Singapore, the 
oligonucleotide probes were designed based on these two genotypes. 
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3.3 Greater than 400-fold Enrichment of HBV DNA Achieved 
As shown in Figure 3.4, greater than 400-fold enrichment of HBV 
sequences with negligible background was achieved using the HBV 
enrichment protocol.  The HBV-enriched DNA libraries from 48 pairs of HCC 
patient samples were sequenced using the GS-FLX genome sequencer.  The 
sequencing generated reads with lengths ranging from 34 to 1,185 bps and 
averaging 255 bps.   Analysis of the sequencing data revealed that ~98% of 
the sequencing reads can be mapped to the patient samples based on the 
identification barcodes.  HBV-containing reads were assembled into 310 
contigs with 204 remaining unassembled and these contigs/reads were 
distributed amongst 43/48 (89.6%) patients (Figure 3.5).  A total of 93 
structural alterations in the HBV genome (including 57 deletions, 31 
inversions and 5 duplications) and 97 integration events in the host genome 
were identified (Figure 2.7).  Of the 43 patients, 39.5% carry HBV sequences 
that have been altered by deletions, inversions or duplications and 60.5% have 
integrated HBV (Figure 3.5).  Majority of the patients were infected with HBV 
of either genotype B (60.4%) or C (34.9%) while 4.7% were infected with 

































HBV gene primers Human gene primers
1 1 1 1 1 1 1 1
 
Figure 3.4: Assessment of HBV enrichment specificity.  HBV DNA was 
enriched >400 fold.  (Reprinted by permission from Oxford University Press. 











Patients with HBV reads
Patients without HBV reads
VH: Viral-human 
aV: Altered HBV (including 
deletions, duplications and 
inversions)
uV: Unaltered HBV  
Figure 3.5: Percentage of patients carrying different types of HBV 
sequences.  (Reprinted by permission from Oxford University Press. 
Carcinogenesis. Toh et al., 2013; 34(4):787-98.) 
 
3.4 HBV Integrations are Predicted to Disrupt Host Gene Regulatory 
Element Binding Sites (REBS) 
Although HBV has been reported to integrate into the host genome at a 
high frequency, it remains controversial whether there are preferential 
sites/regions within the host genome for these integration events to take place.  
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We therefore first analyzed the sequencing data with the aim to answer this 
question. 
As shown in Figure 3.6, a total of 57 and 40 integration events were 
detected in 22 tumor and 13 non-tumor samples, respectively.  Some of the 





























Figure 3.6: Number of integration sites detected in the NT and T samples 
of 48 HCC patients. 
 
Although not statistically significant, some enrichment of integration 
sites was observed in genic regions in tumor but not non-tumor samples 
(Figure 3.7A).  However, when we analyzed the different functional regions of 
the host genome separately, we found that there was statistically significant 
enrichment of integration into the promoters of genes (P < 0.001) in tumor 
samples (Figure 3.7B).    Integrations in the promoters of 5/7 (71.4%) genes 
were predicted to disrupt one or more transcription factor binding sites (TFBS) 
(Figure 3.7C).  Nine of the 12 promoter integrations occurred in tumor 
samples of 6 individual patients in 4 different genes.  Notably, in tumors of 5 
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patients, HBV integrated into the promoter of the TERT gene which has been 
well established to be implicated in various cancers (Figure 3.7C).  
Interestingly, the closer HBV is integrated to the transcription start site (TSS) 
of TERT gene, the higher was the mRNA expression of TERT (Figure 3.7C, 
right) suggesting that viral sequences may act as enhancers [202] to cis-
activate the downstream gene.   
Another noteworthy observation is that HBV integration site at the 
promoter of KPTN overlaps with the 3’-UTR of the NAPA gene such that 
HBV integration is predicted not only to disrupt SP1 transcription factor 
binding site (TFBS) of KPTN, but also disrupt miR-762 and miR-185* 
binding sites in the 3’-UTR of NAPA (Figure 3.7C).  This suggests that when 
analyzing specific genes affected by HBV integrations, overlapping genes 
have to be taken into consideration as well.   
HBV was found to be integrated into the coding exons of tumor of 
only 2 HCC patients.  In one patient, HBV integration into exon 6 of KRT32 
gene which is 448 aa long was predicted to cause premature stop codon 
(Figure 3.7C) potentially encoding a 403 aa truncated KRT32-HBV chimeric 
protein containing only 3 aa coded from HBV sequences.  HBV integration 
into exon 37 of 2768 aa long TG gene was predicted to potentially encode for 
a TG-HBV chimeric protein encoding 2167 aa from TG and >71 aa from the 
reverse complement of HBV. 
While integration into coding exon is rare, greater than 68% of the 
genic integrations occur in the introns of genes.  Interestingly, approximately 
24% of the intronic integrations occurred within 400 bps from the intron-exon 
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boundaries of annotated genes of which 5 were predicted to disrupt intronic 
splicing regulatory element (ISRE) binding sites (Figure 3.7C) suggesting that 
splicing regulation may be affected.  Remarkably, an intronic integration in 
the tumor of an HCC patient predicted to disrupt an ISRE binding site was 
observed to reside 383 bps upstream an alternatively spliced exon (EAS) in the 
FAS, an apoptosis-inducing gene. To test the hypothesis that disruption of 
ISRE site upstream of the EAS of FAS gene in the tumor will lead to 
differential expression of EAS in tumor but not non-tumor sample, primers 
were designed to span and quantitate the EAS (E8 & E9) as well as the non-
alternative, constitutive exon, EC (E3 & E4) in both the non-tumor and tumor 
samples.  As evident in Figure 3.7C (right bottom), significant decrease in the 
amount of EAS compared to EC was observed in the tumor (P < 0.05) where 
HBV integration disrupted the ISRE site but not in the non-tumor sample 
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LOC100507581 - (-) 1 TF (YY1)
LOC100507426 - -
NCOA4 -
(-) 3 TFs (OTX2, PITX2, 
CAR)
DEFB132 - (-) 1 TF (GR)
TERT - (-) 2 TFs (GR, CAR)
TERT - -
TERT - -
TERT - (-) 1 TF (Egr-3)
TERT -
(-) 3 TFs (AP-2, CAR, 
SP1)
TERT - (-) 1 TF (RNF96)
KPTN - (-) 1 TF (SP1)
3' UTR NAPA




Premature stop codon, (-) 
4 ESEs
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AIP - -
POLE2 - -
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Figure 3.7: Integration of HBV into the human genome.  (A) Pie charts 
showing the proportion of genic and intergenic regions in the human genome 
(left) and proportion of HBV integration sites in genic and intergenic regions 
in the non-tumor and tumor samples (right).  (B) Histogram showing the 
number of expected and observed integration sites in the various functional 
regions of the human genome. Exons include 3’UTR. There was statistically 
significant enrichment of HBV integrations in the promoter region in tumor 
(P<0.001) as represented by ***.  The 97 integration events yielded 99 
integration sites due to overlapping of KPTN promoter with 3’-UTR of NAPA 
and NCOA4 promoter with intron 3 of MSMB.  (C) REBS disrupted by HBV 
integrations.  Only integrations occurring in the promoters, exons (including 
75 
3’UTR) and those within 400bps from intron/exon boundaries of genes and 
their spliced variants were included.  RT-qPCR results showed that only tumor 
samples with HBV integrated into the TERT gene expressed the gene at levels 
inversely correlated with the distance of integration site from TSS.  β-actin 
expression was used for normalization.  Data presented are the mean of three 
technical replicates.  Thick single headed arrows represent the orientation of 
the integrated HBV genome relative to TERT gene.  HBV integration into 
intron 7 of FAS gene in the tumor of P37 was predicted to disrupt an ISRE 
binding site located upstream of an alternatively spliced exon (EAS, exon 8).  
Significant decrease in the amount of EAS (relative abundance estimated by 
quantification of boundary of exons 8 and 9) compared to the constitutive 
exon (EC, relative abundance estimated by quantification of boundary of exon 
3 and 4), was observed in the tumor (P<0.05) where HBV integration 
disrupted the ISRE site but not in non-tumor where no HBV integration was 
observed.  Primers used for exon quantification were drawn on top of the 
respective exons.  β-actin was used for normalization.  Data presented are the 
mean of three technical replicates.  Lengths of introns, exons and UTRs were 
not drawn to scale. (-), Disruption of REBS; REBS, Regulatory Element 
Binding Site; ISRE, Intronic Splicing Regulatory Element; ESS, Exonic 
Splicing Silencer; ESE, Exonic Splicing Enhancer; TF, Transcription Factor; 
E, Exon.  Distances are shown in bps. (Reprinted by permission from Oxford 
University Press. Carcinogenesis.  Toh et al., 2013; 34(4):787-98.) 
 
3.5 HBV Integration is Correlated with Differential Gene Expression 
in HCC Patients 
As the expression of TERT gene was found to be correlated with 
integration of HBV into the promoter of this gene, we then examined whether 
HBV integration events are associated with differential gene expression 
between the tumor and non-tumor samples in HCC patients for other genes 
affected by HBV integrations in addition to the TERT gene.  In total, the 
expression levels of 58/99 genes (affected by 56 integration events, due to two 
overlapping genes affected by the same integration events in two cases) are 
available from gene expression microarray.  Of these 58 genes, HBV integrate 
into the promoters, exons and introns of 8, 3, and 23 genes, respectively.  The 
remaining 24 genes are the genes nearest to the integration sites located in the 
intergenic regions.  The other 41 genes with no available expression data are 
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either pseudogenes or affected by HBV integration in patients whose gene 
expression profiles are not available.  Hence, these were not included in the 
analysis. 
As summarized in Figure 3.8, 6/8 (75.0%), 2/3 (66.7%) and 14/23 
(60.9%) of the integrations in the promoters, exons and introns, respectively 
are associated with differential expressions of the affected genes, whereas only 
33.3% of intergenic integrations are associated with differential expression of 
the genes nearest to the integration sites.  We also found that genic (including 
promoters, exons and introns) integrations are significantly correlated with 
differential gene expression compared to intergenic integrations (P<0.05) 
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Figure 3.8: Correlation between integration sites and expressions of genes 
at or in the vicinity of integration sites.  Amongst the 58 genes with 
available gene expression data, 6/8 (75.0%), 2/3 (66.7%) and 14/23 (60.9%) of 
the integrations in the promoters, exons and introns, respectively are 
associated with differential expressions of the affected genes, whereas only 
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8/24 (33.3%) of intergenic integrations are associated with differential 
expression of the genes nearest to the integration sites.  Genic (including 
promoters, exons and introns) integrations are more frequently associated with 
differential gene expression compared to intergenic integrations (P<0.05), as 
represented by *.  A gene is defined as differentially expressed if there is at 
least 1.5-fold difference in the expression between the tumor (T) and non-
tumor (NT) tissues. (Reprinted by permission from Oxford University Press. 
Carcinogenesis.  Toh et al., 2013; 34(4):787-98.) 
 
3.5.1 TERT Gene is Upregulated in >50% of HCC Patients 
As TERT gene is found to be recurrently targeted by HBV integration 
and its expression is upregulated in tumor samples with HBV integration 
compared to the non-tumor samples without integration, we proceeded to 
analyze the expression of this gene in 100 HCC patients using our existing 
gene expression microarray data.   From the gene expression profiling of 100 
HCC patients, the TERT gene was found to be upregulated in >50% of HCC 
compared to their adjacent non-tumor samples as shown in Figure 3.9 
suggesting that the upregulation of this gene is a common event in HCC.  
Multiple mechanisms could be contributing to the upregulation of this gene 
and one of them could be related to integration of HBV enhancer sequences 





































Figure 3.9: Fold change (T/NT) of TERT expression in 100 HCC patients.  
TERT is overexpressed in the tumor (T) compared to adjacent non-tumor (NT) 
samples in >50% of HCC patients.  TERT is defined as differentially 
expressed if there is at least 1.5-fold difference in the expression between the 
T and NT samples.  
 
3.6 HBV preferentially integrate into chromosome 10 in the tumors 
and integration into chromosome 10 is correlated with poorly 
differentiated tumors 
Next, we were interested to know whether HBV preferentially 
integrate into any of the 24 human chromosomes.  Circos plots 
(http://circos.ca/) were employed to visualize and analyze the pattern of HBV 
integrations at the chromosomal level in the tumor and non-tumor samples.   
In the non-tumor samples, relatively random distribution of integration sites 
was observed in various chromosomes.  However, in the tumor samples, 
statistically significant enrichment of integration sites on chromosome 10 (P < 
0.01, after Bonferroni correction) especially in the q-arm was observed (Figure 
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3.10A).  This is the first study that reports preferential integration of HBV into 
chromosome 10 in HCC tumors. 
Notably, HBV integration into chromosome 10 was correlated with 
tumors of higher Edmondson grade which represent poorly differentiated 
tumors (P < 0.05) (Figure 3.10B).  To ensure that this is not a random 
observation, we also randomly sampled the same number of integration events 
located on chromosome 10 using the same pool of total integration sites for 
1,000,000 times.  We then performed Fisher’s exact tests to examine the 
correlation between the randomly selected integration sites and the status of 
tumor grade.  No significant correlation (P>0.05) was observed between the 
randomly sampled integration sites and tumor grade in >99% of the random 
sampling events (data not shown) suggesting that the correlation between 
integration of HBV into chromosome 10 and poorly differentiated tumors is 
not a random observation.   
Other than chromosome 10, there seems to be a certain extent of 
preferential integration into chromosome 17 in the tumor samples, although 
not statistically significant (Figure 3.10A & C).  As shown in Figure 3.10A, 
chromosome 17 is one of the chromosomes with the highest density of 
oncogenes and tumor suppressor genes, suggesting that these genes might be 












































































































































Correlation between patient clinical characteristics and 









Early: I & II (%) 6/7 (85.7) 21/30 (70.0) 
0.6471
Late: III & IV (%) 1/7 (14.3) 9/30 (30.0) 
Histological Grade 
(Edmondson)
Low: I & II (%) 0/8 (0) 15/32 (46.9) 
0.0162* 
High: III & IV (%) 8/8 (100) 17/32 (53.1) 
Tumor Size
≥4cm (%) 5/8 (62.5) 30/35 (85.7) 
0.1533
<4cm (%) 3/8 (37.5) 5/35 (14.3) 
Relapse (%) 4/7 (57.1) 10/30 (33.3) 0.3895
Tumor Capsule (%) 6/8 (75.0) 17/28 (60.7) 0.682
Tumor Necrosis (%) 6/8 (75.0) 17/30 (56.7) 0.4398


























Figure 3.10: Characteristics of HBV integration sites and correlation with clinical characteristics. (A) Distribution of integration sites in 
the HBV genome and human chromosomes represented in circos plots.  Blue, HBV genome; Red, Human genome; Green, HBV genes (P, 
Polymerase; PreC/C, Precore/Core; S, Surface; X, X) and the 24 human chromosomes.  The purple and orange histograms represent the 
densities of tumor suppressors and oncogenes respectively, in each chromosome.  Circled regions at HBV represent preferential sites within 
HBV that integrate into host genome in both non-tumor and tumor samples (***: P<0.001).  Circled region in human chromosome 10 represents 
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statistically significant (**: P<0.01) enrichment of integration sites in tumor samples even after multiple test correction.  (B) Correlation 
between patient clinical characteristics and HBV integration into chromosome 10.  HBV integration into chromosome 10 was significantly 
correlated with higher grade or more poorly differentiated tumors (P<0.05).  Statistical test performed was two-tailed Fisher’s exact test.  The 
numbers in brackets represent percentage of patients with each characteristic.  (C) Rate of integration on each chromosome.  Rate of integration 
is calculated by: Number of integration sites/length of chromosome (in billion bps). (Modified from Toh et al., Carcinogenesis, 2013; 34(4):787-
98 by permission of Oxford University Press) 
 
82 
3.7 HBV Preferentially Integrate into Cancer-related Genes in 
Tumors 
At the gene level, although no specific genes were recurrently targeted 
by HBV other than the TERT gene, 14 out of 97 HBV integration events were 
found to reside within cancer-related genes of which 6 were at the promoter of 
the TERT gene while 8 were within introns of oncogene (ERBB4) and tumor 
suppressor genes (CCNA2, MSMB, MYO18B, AIP, NTN1, FAS) (Appendix F).  
Most of the other integration sites were ~270 kbps (40-31,300 kbps) from 
cancer-related genes (Appendix F).   
Pathway analysis of the genes at or nearest to the integration sites 
using Ingenuity Pathway Analysis (IPA, http://www.ingenuity.com/) revealed 
that most of the genes affected by HBV integration in the tumor samples are 
key genes involved in cell death and survival, cell cycle, and DNA replication, 
recombination and repair (Figure 3.11).  However, in the non-tumor samples, 
most of the genes affected are not categorized under key cellular functions 
although a few are being categorized under cell growth and proliferation, cell 
cycle, and cell death and survival (Figure 3.11). 
Strikingly, analysis of the genes in which HBV integration occurred in 
the genic [including promoters (5kb upstream of TSS), exons (including 
3’UTR) and introns] regions in the tumor and non-tumor samples revealed that 
the genes affected by integration in the tumor samples have the primary 
functions of controlling cell cycle, cell death and survival, DNA replication, 
recombination and repair while those in the non-tumor samples are involved 
mainly in cellular function and maintenance and cellular assembly and 
organization (Figure 3.12).  These findings suggest that HBV may integrate 
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randomly into genes not directly related to cell growth and viability at the 
initial stage of viral infection.  Integration events that affect genes related to 
cell cycle checkpoint or DNA repair may be selected in the process of 
neoplastic transformation. 
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Figure 3.11: Top 10 significantly (P<0.05) enriched molecular and cellular 
functions potentially affected by HBV integration.  The molecular and 
cellular functions are sorted according to the –log(p-value).  Genes included in 
the analysis consist of those of which HBV integration occurred in the genic 
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Figure 3.12: Top 10 significantly (P<0.05) enriched molecular and cellular 
functions affected by HBV integration in the genic region.  The molecular 
and cellular functions are sorted according to the –log(p-value).  Genes 
included in the analysis consist of only those of which HBV integration 
occurred in the genic regions. 
 
 
3.8 Preferential Integration at the 3’-end of HBx and 5’-end of 
Precore/Core 
Other than examining the potential “cis” effect of HBV integration, i.e. 
the effect on the host genome, we also examined the effect of these integration 
events on the viral genome (“trans” effect).  With regards to the viral genome, 
statistically significant enrichment of integration events were observed at 
nucleotides 1600-1900 around the 3’-end of the HBx and 5’-end of the 
Precore/Core genes in both tumor (P < 0.001) and non-tumor (P < 0.001) 
samples (Figure 3.10A & Figure 3.13A).  This region of integration within the 
HBx gene correlated with lower sequencing reads at the 3’-end of HBx gene as 
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demarcated by the two vertical lines (Figure 3.13B & C).  As evident in Figure 
3.13B & C, the region at the 3’-end of HBx gene frequently involved in 
integration is covered with lower number of sequencing reads compared to 
other region of the short (465nt) HBx gene.  The beginning of HBx gene is 
represented by ~450 reads and gradually decreased to ~200 at the 3’-end, 
especially in the region which is most frequently involved in integration into 
the host genome.  The increase of coverage at the extreme end of HBx is 
probably due to the frequent occurrence of integrations at the beginning of 
Precore/Core (which overlaps with 3’-end of HBx), thereby retaining part of 
the extreme end of HBx sequences (Figure 3.13B).  When the gross structure 
of the HBx gene was examined in a different cohort of 49 HCC patients, the 
3’-end of HBx was found to be deleted in 49% of tumor but only 28.6% of 
non-tumor samples (Figure 3.13D), consistent with the observation that higher 
proportion of integration sites occurring at the 3’of HBx gene was observed in 
tumor (56.1%) compared to non-tumor (42.5%) samples (Figure 3.13A).  
Hence, these observations suggest that upon HBV integration, the 3’-end of 
the HBx gene is often deleted. 
Taking a closer look at the exact sites within the viral genome 
preferentially involved in integration, we observed that 10% and 15.8% of the 
integration sites identified in the non-tumor and tumor samples, respectively, 
are located in the 5’-CTTTTT-3’ topoisomerase I motif (nt 1820 to 1825) and 
the DR1 region (nt 1824–1834).  None of the integrations were found to occur 
within the DR2 region (nt 1590-1600).   It is also interesting to highlight that 
in 4 of the integrations found in the tumor samples, the site of integration was 
located at nt 1820 which is the beginning of the topoisomerase I motif, 
86 
strongly suggesting that topoisomerase I may be involved in the integration of 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































% Full length 61.2 32.7
% 3' deleted 28.6 49.0
% 5' deleted 0.0 0.0
% Undetected 10.2 18.4
Total 100.0 100.0








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3.13: Preferential integration at the 3’-end of HBx and 5’-end of 
Precore/Core in the HBV genome.  (A) Distribution of sites within HBV 
genome that integrate into host genome according to sample type.  The 
proportions of integrations occurring within the 3’-end of HBx and 5’-end of 
Precore/Core are 42.5% and 56.1% in the non-tumor and tumor samples 
respectively.  (B) Distribution of sites within HBV genome that integrate into 
host genome according to the location of human sequences relative to HBV 
genes. (C) Coverage of HBV genome in the FLX sequencing.  (D) Table 
showing the summary of gross structure of HBx gene in a separate cohort of 
49 HCC patients. (Reprinted by permission from Oxford University Press. 




3.9 Different Patterns of Structural Alterations in HBV Genome 
between the Tumor and Non-tumor 
Other than the integration events disrupting the 3’-end of HBx and 5’-
end of Precore/core, we also examined whether there are other structural 
alterations within the viral genome.  Structural alterations within the HBV 
genome was observed in 39.5% of the HCC patients examined (Figure 3.5).  
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Figure 3.14: Experimental validation of representative contigs/reads 
containing alteration in HBV.  Gel photos show the results of validation by 
PCR using primers designed at the two ends of reads/contigs.  Blue and red 
arrows indicate single sequencing reads and assembled contigs, respectively.  
Forward and reverse directions of arrows indicate forward and reverse strand 
of the viral genome, respectively. (Reprinted by permission from Oxford 
University Press. Carcinogenesis.  Toh et al., 2013; 34(4):787-98.) 
 
As evident from the circos plots (Figure 3.15), deletion events (green) 
constitute the majority of the alterations in tumor (56.1%) and non-tumor 
(69.4%) samples followed by inversions (red) (38.6% in tumor, 25% in non-
tumor samples) while duplication events (black) were rare.  Interestingly, the 
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‘hotspot’ region for HBV integration was also found to be statistically 
enriched for structural alterations in both the non-tumor (P < 0.001) and tumor 
(P < 0.001) samples (Figure 3.15) which could also account for the low 
sequencing reads in this region and the deletion of the 3’-end of HBx gene as 
well.  Nonetheless, while this ‘hotspot’ region was enriched in deletion (P < 
0.001) and inversion (P < 0.001) events in tumor, it was only enriched for 
inversion events (P < 0.001) in non-tumor samples (Figure 3.16) suggesting 




Figure 3.15: Structural alterations in HBV genome represented by circos 
plots.  The region spanning nucleotides 1600 to 1900 of the HBV genome was 
statistically enriched as sites for structural alterations in both the non-tumor 
(P<0.001) and tumor (P<0.001) samples, as circled and represented by ***.  
Green, Deletions; Black, Duplications; Red, Inversions.  Regions 
encompassed by the two ends of the curvy lines represent deleted or 
duplicated regions.  (Reprinted by permission from Oxford University Press. 









Figure 3.16: Structural alterations (deletions and inversions) in HBV 
genome represented separately in circos plots.  Green, Deletions; Red, 
Inversions.  Regions encompassed by the two ends of the curvy lines represent 
deleted regions.  The region spanning nucleotides 1600 to 1900 of the HBV 
genome was statistically enriched as sites for deletions (P < 0.001) and 
inversions (P < 0.001) in the tumor but only inversions (P < 0.001) in the 
non-tumor samples, as circled and represented by ***.  (Reprinted by 
permission from Oxford University Press. Carcinogenesis. Toh et al., 2013; 
34(4):787-98.) 
 
3.10 HBx-host Chimeric Transcripts are Expressed only when 
Integrations Occur at the 3’-end of HBx  
Next, we asked whether the integrated viral DNA are expressed and 
whether the human sequences adjacent to the integration sites are expressed 
along with the viral genome to form chimeric transcripts.  Interestingly, 
amongst the experimentally validated reads/contigs with HBV-host sequences, 
chimeric transcripts were observed only when the site of integration was at the 
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Figure 3.17: Experimental validation of representative contigs/reads 
containing both viral and human sequences.  Amongst the experimentally 
validated contigs/reads containing both HBV and human sequences, chimeric 
transcripts were observed only when the site of integration was at the 3’ end of 
HBx gene.  When the sites of integration occurred at the 3’ end of other HBV 
genes such as the surface or the polymerase gene or 5’ ends of HBc, no 
chimeric transcript was detected.  Black boxes, HBV sequences; White Boxes, 
Human sequences; RT+, Reverse transcription reaction; RT-, No RT control; 
C, cDNA; G, Genomic DNA.  The numbers labeled on top of gel photos are 
different temperature at which PCR reactions were performed.  (Reprinted by 
permission from Oxford University Press. Carcinogenesis. Toh et al., 2013; 
34(4):787-98.) 
 
Full transcript sequences for 3 HBx-host chimeric transcripts were then 
characterized using the 5’- and 3’ RACE.  These transcripts were found to be 
between 2-2.8kb long, suggesting that a large portion of the HBV genome are 
frequently integrated and expressed.  Open reading frame (ORF) prediction 
from these transcript sequences revealed the presence of ORFs for HBx-host 
chimeric protein with intact HBx start codons in all 3 cases (Figure 3.18A & 
Appendix G).   
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The 3’-end of the HBx gene was then further characterized at the 
transcript level in 23 patients to further evaluate the significance of this 
‘hotspot’ region of integration.  Majority of the HBx transcripts observed were 
HBx-host chimeric transcripts (tX-H) (45.5% in tumor, 55.9% in non-tumor) 
followed by truncated HBx (tX) (33.3% in tumor, 23.7% non-tumor), then 
full-length (FL) HBx transcripts (18.2% in tumor, 11.9% in non-tumor) with 
HBx fused to other HBV sequences (3% in tumor, 8.5% in non-tumor) being 
the least abundant (Figure 3.18B).  Upon further analyses of the extent of 3’ 
deletion in the HBx transcripts, we found that the DDB1 binding domain of 
HBx was rarely deleted (Figure 3.18C).  Interestingly, the trans-activation 
domain but not the p53 binding domain was conserved in 63.5% and 66.7% of 
the HBx transcripts in the non-tumor and tumor samples, respectively.  These 
data suggest that in majority of the patients, altered HBx transcripts encode 
altered proteins that may affect their binding to the p53 master regulator but 
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Figure 3.18: Characterization of HBx transcripts in HCC patients.  (A) 
Sequencing of full length HBV-host chimeric transcripts revealed the presence 
of HBx-host chimeric protein ORFs.  Dashed lines, Deletions in HBV; Arrows, 
ORFs predicted; White boxes, HBV sequences; Grey boxes, Human 
sequences.  The two numbers on top of white boxes indicate the 5’-end of the 
chimeric transcript and the breakpoint in HBV genome upon integration into 
human genome.  The gel photos show that the chimeric transcripts were 
expressed exclusively in the tumor samples.  (B) HBx-host (tX-H) chimeric 
transcripts represent the most abundant HBx transcripts.  FL, Full length HBx; 
tX-V, truncated HBx fused to other viral genes; tX-H, truncated HBx fused to 
human sequences; tX, truncated HBx transcripts. (C) Breakpoints at the 3’-end 
of HBx.  Upon integration, the 3’-end of HBx is often deleted to different 
extent.  The X-axis of bar graph represents the sites within the HBx gene 
where it is truncated while the Y-axis shows the number of transcripts with the 
breakpoint at specified sites on X-axis.  The different domains of HBx protein 
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are shown below the graph.  (Reprinted by permission from Oxford University 
Press. Carcinogenesis. Toh et al., 2013; 34(4):787-98.) 
 
3.11 HBx-host Chimeric Proteins can be Expressed  
Diverse chimeric proteins were predicted from 17 representative 
chimeric transcripts that were characterized (Figure 3.19A).  Within the same 
patient (e.g. P9, P10, P11 and P12), chimeric ORF predicted in the tumor was 
different from that in the non-tumor samples.  Notably, different variants of 
HBx-host chimeric proteins were predicted to exist even within the same 
sample (e.g. P12T).  Between 3-87 aa from HBx were deleted while 0-33 aa 
from human sequences were included in the predicted chimeric ORFs (Figure 
3.19A). 
Five HBx-host chimeric proteins with different domains of the HBx 
being deleted were selected for over-expression and functional 
characterization.  These chimeric HBx proteins were found to be capable of 
being expressed in cultured Huh-7 liver cells although their steady state levels 
were found to be lower than the FL HBx protein (Figure 3.19B).  As shown in 
Figure 3.19B, other than the truncation of HBx at the C-terminal, there are 
also considerable differences between the predicted amino acid sequences 
between the different mutants and the FL HBx (cloned from the pEco63 
plasmid) which is universally used as the “wildtype” HBx.  It is thus important 
to functionally characterize these naturally occurring complex HBx mutants 
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Figure 3.19: HBx-host chimeric protein can be expressed in liver cell line.  
(A) In silico prediction of representative HBx-host chimeric protein ORFs.  
White boxes, HBx; Grey boxes, Amino acids translated from human or other 
HBV sequences.  The letters in the white boxes indicate the amino acid 
differences between HBx in the non-tumor and tumor.  (B) Expression of five 
representative HBx-host chimeric proteins with various extents of C-terminal 
deletions in Huh-7 cells.  The same vector carrying the CAT gene was used as 
a negative control (NC).  GFP expression was used to assess transfection 
efficiency.  (Modified from Toh et al., Carcinogenesis, 2013; 34(4):787-98 by 
permission of Oxford University Press) 
 
3.12 HBx-host Chimeric Proteins Lost the Growth-suppressive Ability 
The FL HBx protein was reported to induce apoptosis 
[143,149,153,155,203-211].  We then investigated the pro-apoptotic ability of 
the different HBx-host chimeric proteins using the colony formation assay.  In 
two independent experiments, when the cells transfected with the various 
mutant HBx, FL HBx and control constructs were treated with either 1.5 
µg/ml or 4.5µg/ml of blasticidin, the FL HBx transfected cells yielded no 
colonies at all similar to the untransfected well after 3 weeks of selection 
whereas considerable number of colonies were observed for all other wells 
transfected with the different mutant HBx and control constructs (Figure 
3.20A & B).  These data suggest that the FL HBx possesses growth 
suppressive ability while the C-terminal truncations in the HBx-host chimeric 
proteins appear to abrogate the growth suppressive ability which also implies 
that these HBx mutants may have a role to play in the first step of 
carcinogenesis.  However, it is worth mentioning that despite various studies 
reporting the pro-apoptotic ability of FL HBx protein, in hepatocarcinogenesis, 
preneoplastic and neoplastic cell populations show an increased rate of 
apoptosis as well as cell proliferation [212].  So, it is in fact a balance between 
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Figure 3.20: HBx-host chimeric proteins lost the growth-suppressive 
ability of full length (FL) HBx.  Colonies formed after 3 weeks of selection 
using blasticidin at (A) 1.5 μg/mL and (B) 4.5 µg/mL.  Colonies were 
observed for all wells except for the FL HBx transfected and the untransfected 
(UT) wells.  NC: Negative control (vector carrying the CAT gene). 
 
3.13 HBx Protein is Over-expressed in the Tumors of HCC Patients 
We have also examined the expression of HBx protein in the tumor 
and non-tumor samples of 103 HCC patients.  The western blot images can be 
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found in Appendix H.  We found that in majority (76.7%) of the patients, HBx 
is expressed at a higher level in tumor compared to their adjacent non-tumor 
samples (Figure 3.21).  Interestingly, although different forms of HBx 
transcripts were observed, only HBx proteins of approximately 17kDa were 
primarily detected.  These ~ 17kDa proteins might include full length, slightly 
truncated HBx proteins or HBx-host chimeric proteins.  Other HBx mutants 
with more deletions were not detected probably due to lower 
stability/expression. 
In fact, as shown in Figure 3.22, the steady state level of HBx proteins, 
especially the mutant HBx proteins can be increased by the treatment of 
proteasome inhibitor (MG132), suggesting that the proteins are constantly 
being degraded via the proteasome-mediated pathway.  Interestingly, the FL or 
near FL HBx proteins (from P2T)  appear to have a higher steady state level 
compared to the different forms of mutant HBx proteins even in the absence of 
proteasome inhibitor.  This may explain why in the HCC patients, only the FL 
or near FL HBx proteins were detected.  Nonetheless, it is also possible that 
the mutant HBx proteins which were not detectable in HCC samples are 
important to the onset rather than the persistence of liver cancer.  In other 
words, continued expressions of these viral proteins are not required to 









Figure 3.21: Proportion of patients with expression of HBx protein higher 
in T (T>NT), NT (NT>T) and similar between NT and T (NT~T).  A total 
of 103 HCC patients were profiled.  HBx is defined as differentially expressed 
if there is at least 1.5-fold difference in the expression between the tumor (T) 
and non-tumor (NT) tissues. 
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Figure 3.22: Steady state level of HBx protein can be increased by 
treatment with proteasome inhibitor.  GFP expression was used to estimate 
for transfection efficiency.  FL: Full length HBx; NC: Negative control; 
MG132: Proteasome inhibitor. 
 
3.14 Mutant HBx Proteins Deregulate Important Cellular Genes in 
HepG2 Cells 
As the FL HBx is well-established to be implicated in HBV-related 
liver oncogenesis, we asked the question of whether these mutant HBx 
proteins also play some role in the process.  To elucidate the possible role of 
these mutant HBx proteins in HCC, we examined the effect of 4 mutant HBx 
from P1T, P2T, P9NT, P9T and the FL HBx on the gene expression profile of 
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HepG2 cells in order to determine whether there is any differentially 
expressed genes between the cells expressing these mutant HBx compared to 
those expressing the FL HBx proteins.  In total, 108 genes were found to be 
differentially expressed between the cells expressing the different mutant HBx 
compared with those expressing the FL HBx.  The list of genes differentially 
expressed by the 4 mutant HBx compared with the FL HBx proteins as well as 
the fold change (Mutant vs FL) are shown in Table 3.2.  Overall, the mutant 
HBx proteins deregulate several but not significant number of genes compared 
to the FL HBx suggesting that both FL and mutant HBx proteins may play 
complementary or synergistic role in the process of hepatocarcinogenesis.  
Notably, when these differentially expressed genes were categorized 
according to their molecular and cellular functions using the Ingenuity 
Pathway Analysis (IPA) software, most of the genes were significantly 
categorized under critical cellular functions such as cell growth and 
proliferation as well as cell death and survival (Table 3.3), suggesting that 
these mutant HBx proteins might regulate important cellular processes 
differentially from the FL HBx.  Some interesting genes that are upregulated 
include the BCR (a GTPase-activating protein for RAC1 and CDC42) and 
INO80B (which induces growth and cell cycle arrests at the G1 phase of the 
cell cycle) and downregulated include the GLTSCR2 which is a putative tumor 










Table 3.2: List of differentially expressed genes between 4 mutants and 
the FL HBx proteins and the fold change (Mutant vs FL).  Only genes with 
fold change (FC) of >|1.5| (differentially expressed) between the mutant and 
FL HBx expressing cells are included. 
 
SYMBOL P1T P2T P9NT P9T
LOC643431 -1.5 -1.4 1.0 -1.0
LOC645688 -1.6 -1.6 -1.5 -1.7
LOC646135 1.5 1.3 1.3 1.7
LOC646734 1.8 1.5 1.8 2.4
LOC647456 1.1 1.3 1.1 1.6
LOC647488 1.6 1.1 1.3 1.1
LOC648210 -1.5 -1.5 -1.2 -1.3
LOC651668 1.4 1.3 1.2 1.7
LOC652750 -2.2 -1.9 -1.4 -1.6
LOC653421 3.1 2.7 2.6 3.2
LOC653820 1.5 1.3 1.2 1.5
LOC727751 3.2 2.0 1.5 1.6
LOC728262 2.0 1.8 1.8 2.3
LOC729500 -1.8 -1.8 -1.7 -2.0
LOC730432 -1.4 -1.3 -1.4 -1.5
LOC732165 1.4 1.1 1.4 1.6
LOC91561 -2.0 -1.9 -1.6 -1.9
LRRC58 1.3 1.4 1.3 1.8
MIR1974 2.2 1.2 1.4 1.7
NCBP2 -1.5 -1.4 -1.2 -1.3
NDUFB7 -1.5 -1.3 -1.2 -1.2
NFKBIZ -1.1 -1.1 -1.1 -1.6
NR3C1 1.5 1.4 1.4 1.9
NY-REN-7 1.3 1.3 1.2 1.6
PGAM4 -2.0 -2.0 -1.8 -2.2
PGAM5 -1.3 -1.3 -1.2 -1.6
PHF16 -1.4 -1.3 -1.4 -1.5
PIM1 -1.6 -1.3 -1.4 -1.2
PPME1 -2.1 -1.8 -1.6 -1.5
PTGES2 -1.6 -1.3 -1.3 -1.3
RER1 -1.2 -1.6 -1.1 -1.2
RFT1 1.4 1.3 1.2 1.5
RGS12 1.4 1.3 1.1 1.6
RHOBTB1 1.6 1.6 1.5 2.0
RIMS4 1.3 1.2 1.3 1.6
RIN2 -1.4 -1.4 -1.4 -1.5
RN5S9 1.4 1.4 1.5 2.0
RNU1A3 -1.1 -1.2 -1.2 -1.5
RNU4ATAC -1.1 -1.2 -1.1 -1.7
RPL12 -1.7 -1.6 -1.5 -1.6
SASS6 2.0 1.9 1.7 3.0
SIVA -1.6 -1.1 -1.0 -1.0
SRI -1.7 -1.5 -1.5 -1.7
TELO2 -2.0 -1.8 -2.3 -1.5
TGIF1 -1.4 -1.4 -1.3 -1.7
TJP1 -1.6 -1.4 -1.4 -1.4
TMEM90A 1.4 1.3 1.3 1.7
TRIB1 -1.3 -1.3 -1.4 -2.0
TSR1 1.0 -2.9 1.0 1.1
TTTY14 2.1 2.0 1.8 2.5
TXNIP -1.4 -1.4 -1.4 -1.6
WDR79 -1.4 -1.4 -1.3 -1.7
XPA 1.2 1.3 1.1 1.5
ZNF519 -1.2 1.8 1.4 -1.1
SYMBOL P1T P2T P9NT P9T
ACADVL -1.9 -1.5 -1.3 -1.4
ALDH5A1 -1.5 -1.3 -1.4 -1.3
ANGPTL4 1.3 1.3 1.3 1.5
ANKRD1 -1.6 -1.5 -1.6 -1.8
ANKRD35 1.1 1.2 1.0 1.6
ATF3 -1.5 -1.4 -1.5 -1.5
ATP5J -1.6 -1.4 -1.5 -1.5
B3GNT8 1.3 1.3 1.2 1.6
BCR 2.0 2.1 1.6 2.5
C14orf179 1.8 1.7 1.8 2.0
C15orf52 -1.3 -1.2 -1.2 -1.6
C19orf43 -1.6 -1.3 -1.2 -1.2
C19orf6 -1.6 -1.5 -1.3 -1.4
C20orf55 1.4 1.4 1.4 1.7
C2orf34 1.3 1.3 1.3 1.5
C9orf144B 1.3 1.3 1.4 1.5
CBWD3 -1.6 -1.5 -1.4 -1.7
CHRNB3 2.1 1.9 1.8 2.7
COX18 1.6 1.7 1.3 2.1
CRYAB -1.4 -1.4 -1.3 -1.5
CTTN -1.6 -1.4 -1.4 -1.6
CXCL2 -1.1 -1.3 -1.2 -1.5
CXCR7 -1.4 -1.3 -1.3 -1.6
DLK2 1.6 1.5 1.5 1.9
DPYSL5 1.7 1.6 1.3 1.6
EDN1 -1.6 -1.4 -1.6 -1.9
EEF1D -1.6 -1.3 -1.1 -1.2
EID3 -1.5 -1.4 -1.5 -1.7
EIF3I -1.5 -1.3 -1.2 -1.2
FBXW7 1.5 1.4 1.1 1.4
FGL1 1.2 1.3 1.2 1.5
FLJ39739 2.8 1.9 1.5 2.0
FLJ41941 1.7 1.5 1.4 2.1
GGT2 1.5 1.4 1.4 1.7
GLTSCR2 -5.5 -3.7 -3.1 -3.5
GPC6 1.4 1.2 1.4 1.6
GPR177 -1.6 -1.4 -1.3 -1.4
HIST2H2AA4 -1.5 -1.6 -1.3 -1.4
HSPA6 -1.7 -1.3 -1.2 -1.2
IFI6 1.1 1.2 1.2 1.5
IL8 -1.2 -1.3 -1.3 -1.7
INO80B 15.0 9.6 5.0 7.1
IRX1 1.4 1.2 1.3 1.8
JUN -1.5 -1.3 -1.4 -1.8
KCNJ4 1.6 1.5 1.3 1.9
LANCL1 -1.3 -1.3 -1.3 -1.7
LASS2 -1.6 -1.3 -1.3 -1.4
LOC100127918 -1.6 -1.4 -1.3 -1.4
LOC100130123 1.1 1.2 1.4 1.6
LOC100130663 1.8 1.7 1.7 2.2
LOC100132761 1.1 1.2 1.4 1.6
LOC100133478 1.5 1.5 1.5 1.7
LOC392437 -3.8 -3.6 -3.4 -4.8
LOC441013 -1.5 -1.6 -1.5 -1.8









Table 3.3: Molecular and cellular functions of genes differentially 
expressed between mutant and FL HBx expressing HepG2 cells. 
Category  p-value Molecules
Cellular Growth and Proliferation 9.57E-04-4.87E-02
IL8, ATF3, TJP1, TXNIP, BCR, FBXW7, NR3C1, XPA, TRIB1, ANKRD1, 
GLTSCR2, ANGPTL4, JUN, EDN1, CXCR7, PIM1, EIF3I, CXCL2, INO80B
Cell Death and Survival 1.32E-03-4E-02
IL8, CRYAB, ATF3, IRX1, BCR, NFKBIZ, NR3C1, XPA, ANKRD1, 
ANGPTL4, JUN, EDN1, CXCR7, PIM1, IFI6, CTTN
Cellular Development 9.57E-04-4.87E-02
IL8, CRYAB, ATF3, TXNIP, BCR, FBXW7, NR3C1, TRIB1, ANGPTL4, 
JUN, EDN1, PIM1, CXCR7, CXCL2, INO80B
Cellular Movement 3.16E-03-4.63E-02
IL8, CRYAB, ATF3, TJP1, BCR, TRIB1, ANGPTL4, JUN, EDN1, PIM1, 
CXCR7, CXCL2, CTTN
Cell Morphology 3.62E-04-4.87E-02
IL8, CRYAB, ANGPTL4, EDN1, TJP1, PIM1, FBXW7, BCR, IFI6, CTTN, 
XPA
Cell-To-Cell Signaling and Interaction 4.52E-03-4.87E-02 SRI, IL8, CRYAB, EDN1, PIM1, TJP1, BCR, CHRNB3, CXCL2, CTTN
Cellular Function and Maintenance 4.52E-03-4.87E-02 IL8, EDN1, TJP1, PIM1, BCR, IFI6, NR3C1, CTTN, XPA
Gene Expression 9.03E-03-4.87E-02 IL8, JUN, PIM1, EIF3I, BCR, NFKBIZ, NCBP2, NR3C1, TGIF1
Cellular Assembly and Organization 4.52E-03-4.43E-02 IL8, SRI, CRYAB, EDN1, PIM1, TJP1, CTTN, NR3C1
Free Radical Scavenging 1.09E-04-3.56E-02 IL8, CRYAB, EDN1, PIM1, TXNIP, BCR, CTTN
Cell Cycle 2.03E-03-4E-02 JUN, EDN1, TXNIP, PIM1, FBXW7, XPA
Lipid Metabolism 4.21E-03-4.52E-02 IL8, PTGES2, EDN1, NR3C1, ALDH5A1, CERS2
Small Molecule Biochemistry 4.21E-03-4.52E-02 IL8, PTGES2, EDN1, NR3C1, ALDH5A1, CERS2
DNA Replication, Recombination, 
and Repair
4.52E-03-3.18E-02 IL8, JUN, PIM1, BCR, NR3C1, XPA
Molecular Transport 1.09E-04-3.56E-02 SRI, IL8, EDN1, TXNIP, BCR
Cellular Compromise 4.52E-03-3.12E-02 IL8, ANGPTL4, PIM1, CXCL2, NR3C1
Drug Metabolism 4.21E-03-1.35E-02 IL8, PTGES2, EDN1, NR3C1
Protein Synthesis 1.01E-02-2.98E-02 JUN, EDN1, EIF3I, NCBP2
Carbohydrate Metabolism 4.52E-03-4E-02 CRYAB, EDN1
Cell Signaling 5.65E-03-5.65E-03 IL8, EDN1
Amino Acid Metabolism 4.52E-03-4.52E-03 ALDH5A1




Post-Translational Modification 4.43E-02-4.43E-02 PIM1  
3.15 Variations in the HBV Genome are Predicted to Cause Amino 
Acid Substitutions 
As the sequence variations/mutations within the HBV genome have 
been reported to be associated with the clinical outcome of the viral infection, 
we also analyzed the sequence variations within the HBV genome based on 
the HBV sequences obtained from the high-throughput sequencing.  Majority 
of HBV strains identified in this study belong to either genotypes B and C.  
Therefore, sequence variations with respect to these 2 genotypes were 
evaluated.  As evident in Figure 3.23, variability across the entire HBV 
genome was observed for both genotypes B and C when compared with the 
reference sequence of the same genotype.  The polymerase and core genes 
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Figure 3.23: Sequence variations within the HBV genome.  A nucleotide 
different from the reference sequence at a particular position was defined as 
“variant”.  The percentage of variants at each nucleotide position was 
calculated by: (Total number of contigs or reads carrying a specific variant ÷ 
Total number of contigs or reads covering that nucleotide position) × 100%.  
Within both HBV of genotype B and C, some regions of polymerase or core 
genes (as circled) appeared to be more variable compared to other regions.  
(Reprinted by permission from Oxford University Press. Carcinogenesis. Toh 
et al., 2013; 34(4):787-98.) 
 
Through in silico translation, we examined the potential consequences 
of these nucleotide variations at the amino acid (aa) level for the major HBV 
proteins, namely, the Polymerase, Large S, Precore/Core and X protein.  
Overall, there was a significantly higher proportion of non-conservative 
compared to conservative substitutions in both the non-tumor (P < 0.01) and 
tumor (P < 0.05) samples (Figure 3.24A).  These preferential non-
conservative substitutions were observed only in patients infected with HBV 
of genotype C (P < 0.05) but not B (Figure 3.24B).  Notably, in these patients 
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infected with genotype C, the proportion of non-conservative to conservative 
substitution was higher in the HBx protein compared to the other 3 proteins 
(Figure 3.24C) suggesting that preferential non-conservative substitutions 
observed in patients with C genotype were primarily contributed by non-
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Figure 3.24: Sequence variability in the different HBV proteins.  (A) 
Proportions of conservative and non-conservative substitutions in the four 
HBV proteins (X: HBx, C: Precore/Core, S: Large S, P: Polymerase; Ov: 
104 
overall).  **: P<0.01 and *: P<0.05.  (B) Proportions of conservative and non-
conservative substitutions in the four HBV proteins with reference to 
genotypes B and C.  *: P<0.05.  % NC / % C: % non-conservative / % 
conservative substitutions.  (C) Proportions of potential substitution ‘variable’ 
and ‘hotspot’ sites in the four HBV proteins with respect to genotypes B and C.  
(Reprinted by permission from Oxford University Press. Carcinogenesis. Toh 
et al., 2013; 34(4):787-98.) 
 
Further examination revealed several variable sites (defined as 
substitutions occurring in ≥10% of the samples) as well as potential ‘hotspots’ 
(defined as substitutions occurring in ≥20% of the samples) in all four HBV 
proteins analyzed.  The variable sites and hotspots are represented in Figure 
3.25 as downward arrows and boxes, respectively.  Different ‘variable’ and 
‘hotspot’ sites were observed for the 2 different genotypes examined.  The 
HBx and Precore/Core genes have more variable sites than the other 2 genes 
for both genotypes (Figure 3.24C).  The X gene has high proportion of hotspot 
sites as well.  More than half of the ‘hotspot’ sites were non-conservative 
amino acid changes affecting all the viral genes including HBx (V44A/T/G/I, 
R87G (Genotype B) and H94Y (Genotype C)), Precore/Core (W28Stop, 
P164Q/T (Genotype B)), Large S (H51Q and I300N/T (Genotype C)) and 
Polymerase (H305Q, N306H/F/D, T474A, S569A and A663S of Genotype C) 
(Figure 3.25).  These substitutions have the potential to affect the properties or 
structures of the viral proteins and hence alter their function.  The I127V/M 
and K130M in HBx and W28Stop (G1896A) ‘hotspot’ in Precore/Core 
(Figure 3.25A & B) were previously reported to result in substitutions of 
amino acids in HBx protein [213-219] and a premature stop codon at amino 
acid 28 of the precore protein [220-225], respectively.   
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Interestingly, at some hotspot sites e.g. in Large S (S177N and I300T 
of Genotype C) and Polymerase (E16D and S569A of Genotype B and C, 
respectively) (Figure 3.25C & D), the aa that were substituted were of the 
other genotype suggesting either infection with recombinant HBV or co-
infection of HBV of both genotypes within the same sample. 
 
106 
1 2 3 4 5 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154




17N L T T N
18N N A A V N D R S M I
21N
23N A G N R
28N T V S T
33N T G N V
35N S A
37N
39N M P T P N
42N
44N
6T G T N
8T S A
11T
M A T N
G
15T T
18T N A R D V N M
21T G
23T R G V
24T S A S R
28T
33T T G N V
35T V S A F A M
36T P S A R T I M I
37T G V
38T A




1 2 3 4 5 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154
REF M A A R V P A R D V L C L R P V G A E S R G R P V S G P F G T L P S P S S S A V P A D H G A H L A G P C A L R F T S A R R M E T T V N A H Q V L P K V L H K R T L G L S A K D W E E L G E E I R L M I F V L G G C R H K L V C S P A P C N F F T S A
4N A S
5N L C R
10N L D S
16N M R P Y
19N L N S T L R Y Y A




45N L P Q I K K K T R Y T T
4T A
5T L C E K R T
10T L
13T R P R
16T M R P
19T L R Y Y A
20T Y
29T L I T

















5 43 44 87 118 127 130
5 22 32 36 38 42 47 86 94 127
Large S
1 2 3 4 5 6 7 8 9 10 27 39 40 41 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 120 121 122 123 124 125 126 127 128 129 130 137 138 139 140 141 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178
REF M G G W S S K P R K D E N P P H K D N W P D A N K V G V G A F G P G F T P P H G G Q A Q G I L T T V P A A P P P A S T N R Q S G R Q P T P L S M Q W N S T T F H Q T R A L Y F G T V S P A Q N T V S A I S S I L S K T G D P V P N M E N I
8N Q D S E V T V K V K V N V A S S L
9N
14N T L L Q
15N
17N




33N L I V T T
35N Q D S I R P N V A S
37N
6T






23T S L L M D
28T
30T
33T E Q L H I
35T Q D S L L
36T A T F
37T L
39T Q E Q L
44T
1 2 3 4 5 6 7 8 9 10 27 39 40 41 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 120 121 122 123 124 125 126 127 128 129 130 137 138 139 140 141 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178




10N A L T A V V N
16N A S
19N T Q S S T T
20N S
29N G Q A S S S Q K H
32N
40N A T V A N




10T L A N
13T
16T
19T Q S T
20T A V T N




179 180 181 182 183 184 190 191 192 193 194 195 196 197 198 214 215 216 217 218 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 266 267 268 269 270 271 272 273 274 275 288 289 290 297 298 299 300 301 302 303 304 305 306 307 314 315 316 317 318 319 331 332 333 334 335 349 350 351 352 353 354 355 356 357 358 359 360 361 374 375 376 377 378 379 380 381 382 383 384 390 391 392 393 394 395 396 397 398 399 400
REF A S G L L G Q A G F F L L T K N F L G G S Q S Q I S S H S P T C C P P I C P G Y R W M C I F L L V L L D Y Q S T T T C T T P A Q G T S M T K P T D G A F A K Y L L V P F V Q W F V G L S F W G P S L Y N I L S L P I F F C L W V Y I
8N T S P T A S R F
9N A F


























179 180 181 182 183 184 190 191 192 193 194 195 196 197 198 214 215 216 217 218 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 266 267 268 269 270 271 272 273 274 275 288 289 290 297 298 299 300 301 302 303 304 305 306 307 314 315 316 317 318 319 331 332 333 334 335 349 350 351 352 353 354 355 356 357 358 359 360 361 374 375 376 377 378 379 380 381 382 383 384 390 391 392 393 394 395 396 397 398 399 400
REF T S G F L G Q A G F F L L T R N F L G G S Q S P T S N H S P T S C P P I C P G Y R W M C I F L L V L L D Y Q S T T T C T I P A Q G T S M T K P S D G A F A R F L L V P F V Q W F V G L S Y W G P S L Y N I L S L P I F F C L W V Y I
4N S
5N












10T E T N N V Y
13T K N I R V
16T
19T
20T S K S N T
29T L







10 39 55 65 84 120 158
195 374
51 54 6062 73 84 125 177
300
1 15 21 22 23 24 25 26 27 28 29 41 55 56 57 58 67 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 155 156 157 158 159 160 161 162 163 164 172 173 174 175 176 182 183 184 197 198 206 207 208 209 210 211 212
REF M P K L C L G W L W G S S I R D Y E H C S P H H T A L R Q A I L C W G E L M N L A T W V G S N L E D P A S R E L V V S L K I R Q L L W F H I S C L T F G R E T I R T P P A Y R P P L P E T T G R S S Q Q S R E S Q C
8N G
14N T G A G L D Q A C
18N Q
21N I L Q C
22N G F T
23N T A S
33N L I M D I Q A
37N
39N
8T P G L G
11T H V
14T G A G









1 15 21 22 23 24 25 26 27 28 29 41 55 56 57 58 67 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 155 156 157 158 159 160 161 162 163 164 172 173 174 175 176 182 183 184 197 198 206 207 208 209 210 211 212
REF M P K L C L G W L W G S S I R D Y E H C S P H H T A L R Q A I L C W G E L M N L A T W V G S N L E D P A S R E L V V S L K I R Q L L W F H I S C L T F G R E T I R T P P A Y R P P L P E T T G R S S Q Q S R E S Q C
5N S S V I V T C K
10N A V D A
16N T P
19N L I T
20N
29N
40N T M L
45N D A V E L V G E S R S P T P
46N
4T H G V V









116 126 142 159 164 176 209















196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314
REF S F C P Q S P G I L P R S S V G P C I Q S Q L R K S P A Q G Q L A G R Q Q G G S G S I R A R V H P S P W G T V G S G H T H N C A S S S S S C L H Q S A V R K A A Y S L I S T S K G H A V E L H H F P P N S S R S










33N G P H R T H

















33T G P H




39T R I A P
42T
196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314






19N S F M P H A
20N F T S V
29N P S F M S P I S Q Q H F T
32N Q F
40N S




10T T E C S F
13T
16T I V M F F
19T
20T







1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 32 33 34 35 36 37 38 39 45 46 47 48 49 55 67 68 69 70 71 72 73 81 82 83 84 85 86 87 88 89 90 91 92 93 104 116 117 118 135 136 137 138 139 140 141 142 143 144 153 161 162 163 164 165 166 167 168 169 170 171 178 186 187 188 189 190 191 192 193 194 195
REF M P L S Y Q H F R K L L L L D E E A G P L E E G L N R R V A E N L N V S K V P C F N P K D I H L Q E D I V D R C K N Y P N E H V V N H Y F Q T K E S T R S A S F C G S D F Q T S K R H G D K
8N D D S N N I N Q T E L T
9N









35N A T H F E L T
37N Y




8T P D D S I N Q T T E L T
11T L
14T D D P N T K
15T D D












39T E G N T F
42T
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 32 33 34 35 36 37 38 39 45 46 47 48 49 55 67 68 69 70 71 72 73 81 82 83 84 85 86 87 88 89 90 91 92 93 104 116 117 118 135 136 137 138 139 140 141 142 143 144 153 161 162 163 164 165 166 167 168 169 170 171 178 186 187 188 189 190 191 192 193 194 195




10N A G P T
16N D A T A H
19N D N
20N
29N D R K
32N D T D K
40N G
















315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 346 347 353 354 355 356 357 358 359 360 361 362 363 364 403 422 449 450 451 452 453 454 455 468 469 470 471 472 473 474 475 476 477 478 479 480 495 496 497 498 499 509 510 511 512 513 514 521 533 540 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 583 584 595
REF Q S Q G P V L S C W W L Q F R N S E P C S E Y C L C I E T E H G E H R I R T P R S N V G S S G L S I N N Q H R T M Q N L H N K T Y G R I L G F R K L I A V Q H L E S L Y A A V T N F L P H F









28N P D A H D
33N D
























315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 346 347 353 354 355 356 357 358 359 360 361 362 363 364 403 422 449 450 451 452 453 454 455 468 469 470 471 472 473 474 475 476 477 478 479 480 495 496 497 498 499 509 510 511 512 513 514 521 533 540 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 583 584 595
REF Q S E G P I L S C W W L Q F R N S K P C S D Y C L S L E T E H G E H N I R I P R S N V G S S G L P I N Y Q H G T M Q D L H D K T F G R I L G F R K L I A V Q H L E S L F T S I T N F L P N F




16N I S Q A M Q
19N
20N F
29N K T Y H
32N E A V T
40N H A V H




10T F H A E I A R V
13T A M Q V
16T
19T
20T Q A H





46T Y H S
18T
605 606 607 608 609 610 611 612 613 614 615 616 617 624 625 636 653 654 655 656 657 658 659 660 661 662 663 678 679 680 681 682 683 692 693 694 710 711 712 713 714 715 726 727 728 729 730 731 732 733 743 744 745 746 747 777 778 779 780 781 782 783 784 785 793 794 795 796 797 803 804 805 806 807 808 809 810 811 812 813 821 822 823 824 825 826 827 828 829 841 842 843
REF T L P Q E H I V Q K I K M V N I A L M P L Y A C I Q A S K Q Y L N P G L I G H Q R M H T A E L L A A K L I G T F V Y V P S A L N G R L G L R L L Y R P T T G R T S V P S H L P D R R P P




































605 606 607 608 609 610 611 612 613 614 615 616 617 624 625 636 653 654 655 656 657 658 659 660 661 662 663 678 679 680 681 682 683 692 693 694 710 711 712 713 714 715 726 727 728 729 730 731 732 733 743 744 745 746 747 777 778 779 780 781 782 783 784 785 793 794 795 796 797 803 804 805 806 807 808 809 810 811 812 813 821 822 823 824 825 826 827 828 829 841 842 843










40N D I L S M
45N H I P Y F V V F I L
46N
4T S H K
5T I M L N
10T K N
13T T S V
16T
19T
20T L L S
29T L I
31T
34T H S N




16 17 93 104 136 162 178 186 190
198 202 206209 228 235 264 288
805 841
73
213 218 232 237 272 305
306
307






Figure 3.25: Predicted amino acid sequence variations in the four major 
HBV proteins.  (A) HBx, (B) Precore/Core, (C) Large S and (D) Polymerase.  
For viral protein of each genotype, a consensus reference sequence generated 
from alignment of 60 HBV sequences was listed at the top row.  Only amino 
acid residues different from the reference were shown in the figures.  A site 
was defined as variable when ≥ 10% of samples carried residues different 
from the reference sequence at the particular site and was indicated by a 
downward arrow.  A hotspot for single amino acid substitution was defined as 
a site where ≥ 20% of samples carried residues different from the reference 
sequence and was highlighted by black boxes.  The numbers indicate the 
positions of the amino acid residues in a specific protein.  Red, green, blue and 
yellow colors represent non-polar hydrophobic, polar acidic, polar uncharged 
and polar basic amino acids, respectively.  Black color-filled boxes represent 
premature stop codons at amino acid 28 of precore/core protein caused by 
G1896A in the HBV genome.  White areas represent conserved regions that 
were condensed to save space.  B, Genotype B; C, Genotype C.  (Reprinted by 
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CHAPTER 4: DISCUSSION 
* This chapter is adapted from original research article, Soo Ting Toh, 
Yu Jin, Lizhen Liu, Jingbo Wang, Farbod Babrzadeh, Baback Gharizadeh, 
Mostafa Ronaghi, Han Chong Toh, Pierce Kah-Hoe Chow, Alexander Y-F 
Chung,  London L.-P- J Ooi, Caroline G-L Lee (2013).  Deep sequencing of 
the Hepatitis B Virus in Hepatocellular Carcinoma patients reveals enriched 
integration events, structural alterations and sequence variations.  
Carcinogenesis, 34(4):787-98 by permission of Oxford University Press. 
 
Although chronic HBV infection had long been associated with 
significantly higher risk of HCC, its role in hepatocarcinogenesis remains 
unclear.  Due to technological limitations, it was previously challenging to 
comprehensively characterize HBV in HCC patients.  With the recent advent 
of ultra-high-throughput next-generation sequencing (NGS) technology, it is 
now possible to characterize HBV in HCC patients in a more comprehensive 
manner.  In fact, two very recent reports employed paired-end short-reads 
NGS to characterize HBV integration in HCC patients [112,113].  Jiang and 
colleagues [112] performed very deep whole genome sequencing of only 3 
HBV-positive HCC patients and uncovered 255 HBV integration sites while 
Sung and colleagues [113] also performed whole genome sequencing of 81 
HBV-positive HCC patients and identified 399 integration sites in 75 patients.  
In this study, we employed enrichment and pooling strategies to 
comprehensively enrich for HBV DNA sequences in a generally unbiased 
manner from the complex genome of 48 HCC patients for sequencing using 
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the FLX Genome Sequencer.  We identified 97 integration events in 26 HCC 
patients.  Although our cost-effective enrichment-pooling strategy identified 
less integration sites than the other 2 reports, due to the long read length of the 
FLX Genome Sequencer, all integration sites were identified within the same 
read without resorting to paired-end sequencing and the exact nucleotides at 
the integration junction can also be confidently delineated.  Notably, with the 
long reads, we are also able to discover and characterize novel rearrangements 
in the HBV genome which has not been characterized in either of the reports.  
Although the integration of HBV into the human genome superficially seems 
random, several interesting trends were observed as discussed below. 
4.1 HBV Preferential Integration into Regulatory Region and Selected 
Chromosomes 
4.1.1 HBV Preferential Integration into Promoter Region  
As HBV is well-known to be an oncogenic virus, one of the ways that 
this virus may contribute to HCC is probably by disrupting the coding region 
of important cellular genes, causing a loss of function mutation thus promoting 
tumorigenesis.  However, we observed integration of HBV into the exons in 
only 3 cases, with one case in which integration occurring in the 3’ UTR.  
Strikingly, in the tumor but not non-tumor samples, we observed significant 
enrichment of integration into the regulatory region of genes, the promoters.  
This observation was also reported in the recent NGS characterization of HBV 
integration [113].   
Besides the promoter, HBV also integrates into other regulatory region 
of genes such as the introns.  Significantly, HBV integration into the intron of 
the FAS gene predicted to disrupt an ISRE site was found to disturb the 
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balance between the different isoforms within the cell which may have 
different functions under physiological condition [226].  Integration into 
introns might also influence the expression of genes involved as some introns 
might contain enhancer elements or alternative promoters that regulate gene 
expression [227].  Taken together, our data seems to suggest that HBV 
integrations into the host genome have the primary role of affecting gene 
regulation rather than disrupting the coding region directly.   
Interestingly, we also observed a significant association between genic 
(including promoters, exons and introns) integrations and differential 
expressions of the affected genes.  These observations suggest that one of the 
mechanisms responsible for differential gene expressions in HCC patients may 
be related to integration of HBV into genes especially their regulatory regions 
such as the promoters and introns.  Up-regulation of gene expression may be 
due to the integration of viral enhancer sequences while down-regulation of 
genes may be due to deletion of host genomic sequences as a result of viral 
sequence insertions as HBV integrations have been reported to result in 
deletion of both viral and host genomic sequences [117-119]. 
However, there is also evidence of activation of cellular oncogenes by 
integrated viral regulatory sequences over long distances [228] as well as 
regulatory elements being able to act from very far away [229-231].  Fourel et 
al. found that in four woodchuck tumors, the WHV integration sites were 
clustered within <20kb in the win locus located 150-180kb away from the N-
myc2 oncogene on the woodchuck X chromosome [202] and proposed that 
activation of the N-myc2 promoter by the WHV enhancer  over a long distance 
might be a mechanism in liver cell transformation.  Similarly, HBV 
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integration may not activate only genes in the immediate vicinity but also 
those further away from integration sites.  One explanation for the long-range 
activation of genes by integrated viral regulatory sequences is probably related 
to higher order DNA structures, by “looping” of long DNA regions facilitating 
the interactions between the DNA-bound proteins at the promoter of the 
affected gene and the integrated enhancer sequence of HBV. 
4.1.2 HBV Preferential Integration into Chromosomes 10 and 17 in 
Tumors 
In addition to preferential integration into the regulatory region of 
cellular genes, HBV was also found to preferentially integrate into selected 
chromosomes such as chromosome 10 and probably chromosome 17 in the 
tumors.  In fact, HBV integration into chromosome 10 was found to be 
significantly associated with poorly differentiated tumors highlighting the 
clinical relevance of chromosome 10 integration.  Some of the integrations in 
chromosome 10 occurred within cancer-associated genes (e.g. FAS and MSMB) 
suggesting that deregulation of these genes might increase the aggressiveness 
of the tumors.  This observation is consistent with previous studies reporting 
that chromosome 10 showed high instability in poorly or moderately 
differentiated HCC in rat [232].  It is noteworthy that majority of the 
integration in chromosome 10 occurred in the q arm (10q) where loss of 
heterozygosity was reported to be a frequent event in a subset of HCC 
[232,233] suggesting the presence of genes involved in the progression or 
development of HCC in that arm of the chromosome. 
Although not statistically significant, chromosome 17 appears to be 
frequently targeted by HBV integration other than chromosome 10.  
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Chromosome 17 is also one of the chromosomes with the highest density of 
oncogenes and tumor suppressor genes.  The integration events may have 
resulted in partial deletions or rearrangements of these genes on chromosome 
17.  In fact, previous studies have also demonstrated that HBV integrate into 
cellular DNA leading to translocation between chromosomes 17q22 and 
18q11 [117], chromosomes 17 and X [119], Chromosome 17 and 7 [187], 
large inversion of cellular DNA on chromosome 17p11.2-p12 [120] and loss 
of markers from chromosome 17p [171].  The loss of markers from 
chromosome 17 has also been demonstrated for other human cancers, 
including colon cancer [234], bladder cancer [235], lung cancer [236-238] and 
breast cancer [239].  Notably, the gene coding for the famous tumor 
suppressor, p53 is located on chromosome 17p13.1.  It is therefore tempting to 
speculate that this gene may be one of the targets of chromosome 17 
alterations in many human cancers including HCC. 
4.2 HBV Integration into Critical Cellular Genes in Tumors 
Analysis of the genes affected by HBV integrations revealed that more 
integration occurred in genes belonging to critical cellular pathways in the 
tumor compared to the non-tumor samples.  Hence, we propose that during the 
early stage of HBV integration, HBV DNA is integrated throughout the host 
genome to facilitate the retention of the viral genome in the host cells.  In the 
later stage, only cells containing integrated HBV-DNA in unique sites that 
have been selected for survival are retained.  Hence, it is believed that some of 
the integrants detected in the non-tumor samples are merely passenger 
integrants and only those integration events that hit on critical genes or 
combinatory effect of integration with some other insults are able to initiate 
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malignant transformation.  This model has been hypothesized by David A. 
Shafritz in 1982 [161] although at that time there was insufficient 
experimental data to support the hypothesis.  The reason why in the non-tumor 
samples, there are clonal expansions of cells is probably because the 
integration events also confer growth advantage to the cells but not aggressive 
enough to cause uncontrolled cell growth, thus the cells affected by the 
integration were well organized in adjacent “normal” cells.   
In fact, one of the most significant observations in this study as well as 
several others [109-113] is the recurrent integration into the promoter of the 
TERT gene.  Interestingly, we also found that the expression of the TERT gene 
was correlated with the distance of integration sites from the TSS.  As 
telomerase activity is associated with cell proliferation and differentiation 
[240,241], an increase in TERT expression probably due to insertion of viral 
regulatory sequences in the promoter region of this gene may explain the 
mechanism of HBV oncogenesis in a subset of HCC patients, similar to classic 
oncogene activation.  However, telomerase activity has been shown to be 
significantly increased in the tumors compared to non-tumor tissues 
independent of the persistence of the HBV genome [242,243].  In addition, it 
has been reported that retrovirus preferentially integrate into transcriptionally 
active genome regions [244,245].  Therefore, there is also a possibility that the 
TERT gene, being actively transcribed in the tumor samples due to other 
mechanisms, becomes a favorable target for HBV integration.  Nonetheless 
the observation that the distance of integration sites from the TSS of TERT is 
negatively correlated with the expression of this gene somewhat strengthen the 
115 
hypothesis that one of the mechanism of TERT gene upregulation is due to 
insertion of viral enhancer sequences in the promoter region of this gene.   
Notably, amplification of the 5p region in late HCC has been reported 
[246-248] suggesting that upregulation of TERT which is located at 5p15.33, 
may also be due to amplification of this gene.  Nonetheless, there are also 
evidences suggesting that the viral proteins, HBx and preS2 can trans-activate 
TERT [249,250].  All these findings suggest that upregulation of TERT may 
be a central event in HCC and the mechanism of upregulation may differ for 
different individuals.   
4.3 Mechanisms of HBV Integration 
As once the HBV genome is integrated into the host genome, it will 
remain in the host cell unless the cell is removed by host immune mechanism.  
Hence, it is important to understand the mechanism of HBV integration in 
order to target the integration pathway.  An informative way of understanding 
the mechanism of HBV integration is by analyzing the sequences at the viral-
host junctions.  A few mechanisms of HBV integration into the host genome 
have been proposed based on the analysis of the sequences found at the sites 






Figure 4.1: Possible mechanisms of HBV integration.  (A) HBV DNA 
integration occurs when there is a template switching from cellular to single-
stranded gap region of viral DNA during cellular DNA replication, followed 
by recombination between viral and cellular DNA to give the fully integrated 
viral sequence, as proposed by Koshy et al. [162].  (B) Koch et al.  [165] 
added to Koshy’s et al.’s model by proposing that the site of viral integration 
is determined by the partial homology between the viral and host genomic 
DNA.  (C) Dejean et al. [164] proposed the involvement of viral direct repeat 
sequences in the integration process.  (D) Yaginuma et al. [122] suggests that 
integration occur via an incomplete minus strand generated from pre-genomic 
viral RNA during viral replication.  The 3’-end of the incomplete minus strand 
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is joined to the 5’-overhang of a staggered break in human chromosomal DNA.  
The 5’-end of the incomplete minus strand is then joined to the chromosomal 
DNA after removal of the viral DNA polymerase.  (E) Shih et al. [166] 
proposed that the free end at a single-strand break in cellular DNA can invade 
into the HBV genome, forming viral-host junctions.  (F) Hino et al. [251] 
proposed that HBV integration is formed when a cellular polymerase switches 
strands to the invading 3’-end of HBV minus strand at the DR1 sequence.  
(Reprinted by permission from Elsevier Ltd. J. Hepatol. Bonilla Guerrero R 
and Roberts LR, 2005 [37]) 
 
The first mechanism proposed by Koshy et al. [162] involves template 
switching of cellular DNA polymerase from host DNA to the single-stranded 
region of the HBV DNA near the 5’-end of the short strand.  The viral DNA 
then recombines with the cellular DNA and single-stranded regions are filled 
and then ends are ligated to form a fully integrated HBV DNA.  The second 
mechanism proposed by Koch et al. [165] is similar to the first mechanism.  
Koch et al. also suggested that the site of viral integration is determined by the 
partial sequence homology between HBV and the host genomic DNA.  The 
third mechanism proposed by Dejean et al. [164]  suggests the involvement of 
viral DR1 and DR2 repeat sequences in the integration process.  The fourth 
mechanism proposed by Yaginuma et al. [122] suggests that integration occur 
via an incomplete minus strand generated from pre-genomic viral RNA during 
viral replication.  The integration occurs by joining the 3’-end of the 
incomplete minus strand to the 5’-overhang of a staggered break in human 
chromosomal DNA.  Shih et al. [166] proposed that the free end at a single-
strand break in cellular DNA can invade into the HBV genome, forming viral-
host junctions.  Hino et al. [251] proposed that HBV integration is formed 
when a cellular polymerase switches strands to the invading 3’ end of HBV 
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minus strand at the DR1 sequence.  However, all the models were proposed 
based on <10 viral-host junction sequences. 
With the advent of ultra-high-throughput (UHT) sequencing, we are 
now able to analyze more viral-host junctions to more accurately elucidate the 
mechanism of HBV integration.  From our sequence analysis of the 97 viral-
host junctions, we found that the preferential sites within the HBV genome 
involved in integration into the host genome correspond to the region between 
the DR1 and DR2.  Interestingly, a narrow region within the viral genome near 
the DR1 (1824-1834) which is where the HBV genome 
replication/transcription initiate, is strongly preferred to be involved in 
integration into the host genome and structural alterations within the viral 
genome.  We therefore propose that the integration as well as structural 
alteration events may occur via the replication/transcription intermediate of 
HBV which provide free ends near the DR1 region to invade into the host 
genome.  Notably, the topoisomerase I motif (nt 1820-1825) which is adjacent 
to the DR1 is also a highly preferred region suggesting that topoisomerase I 
may also be involved in the process of integration.   
Nevertheless, there are other regions within the viral genome that 
integrate into the host genome, although at a lower frequency.  Therefore, we 
believe that other than the major mechanisms proposed, there are other less 
predominant mechanisms of integrations that gave rise to the rare integrants 
observed in other region of the viral genome.  In addition, our model was 
proposed based on the sequences of viral-host junctions observed in the 
patient samples.  It is possible that the final integrants that we observed are 
results of post-integration modifications such as deletions or chromosomal 
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translocations that hinder us from analyzing primary insertion events which 
would provide the most valuable information on the mechanism of integration.   
4.4 Is HBV Integration a Random Process? 
One of the most challenging questions to answer is whether the HBV 
integration is a random process.  This has remained unanswered for the past 
few decades ever since HBV was found to be able to integrate into the host 
genome.  With the recent emergence of the UHT sequencing, either the 
sequencing of the entire human genome, or the captured HBV DNA from 
HCC patient samples will provide a more comprehensive analysis of the 
sequences adjacent to the integration sites, to help answer this question. 
Based on our data, at the nucleotide level, no specific sequences are 
recurrently observed near the integration sites.  We then examined whether 
HBV integration preferentially occur in/adjacent to certain genes.  The genes 
affected by HBV integrations extracted from various medium to large scale 
studies (from year 2000 to 2012) were compiled and analyzed to look for 
recurrent genes targeted by HBV integration (Table 4.1).  A recurrent gene is 
defined as a gene that is reported to be targeted by HBV integration in more 
than one sample.  As shown in Table 4.1, 27 recurrent genes were identified.  
Remarkably, relatively strong preference (observed in >10 samples) for the 
TERT, MLL4 and the FN1 genes were observed.  Notably, the TERT and 
MLL4 genes were only targeted by HBV integration in the tumor samples, 
whereas the FN1 gene seems to be more frequently targeted by HBV in the 
non-tumor than the tumor samples.  Other than these relatively strong 
preferential targets of HBV integration, genes such as CCNE1, GRID2, 
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LPHN3, NEDD4L and SENP5 are also recurrently targeted in 3-4 samples.  
The rest of the genes are targeted by HBV integration in 2 samples each.   
Taken together, these observations suggest that HBV integration may 
not be influenced much by local sequence content but there is a mild 
preference for certain genes.  In this study, we also found that HBV exhibits 
preferential integration at the chromosomal level.  We identified chromosome 
10 and promoters as preferential region for HBV integration, suggesting that 
although not sequence-specific, there appears to be a certain extent of 
preference for integration events that have functional impact. 
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Table 4.1: List of recurrent genes affected by HBV integration extracted 
from various publications (2000-2012) 








Intron26/10 within 180 NT Wing-Kin Sung et al.; Nature Genetics; 2012
Intron 26 within 19 T This thesis
NA 145.882 31656 NT
NA 270.215 31107 T
Exon12/10/4 within 200 T
Intron2/Promoter within 145 T
Intron2/Promoter within 145 T
Intron4/2 within 106 T
Promoter within 268 T
NA within 31656 NT Zhaoshi Jiang, Suchit Jhunjhunwala et al.; Genome Research; 2012
intron within 339P NT
intron within 339P NT
NA <10kb 09HP-31 NT
intron within 339P NT
NA within H442 NT Zhaoshi Jiang, Suchit Jhunjhunwala et al.; Genome Research; 2012
intron within 09HP-12 NT Suzhen Jiang, Ziwei Yang et al.; PLoS One; 2012
Downstream 14 8A T Y Murakami et al.; GUT; 2005
NA within 31656 NT
NA within 31656 NT
Intron1 within 95 NT
Intron12 within 180 NT
Intron2 within 182 NT
Intron3 within 126 NT
Intron5 within 117 NT
intron within 09HP-2 NT
intron within 09HP-9 NT
exon within 09HP-10 NT
intron within 09HP-27    NT
intron within 09HP-32 NT
intron within 09HP-64 NT
intron within 09HP-65 NT
intron within 09HP-68 NT
intron within 09HP-68 NT
intron within 09HP-68 NT
intron within 09HP-70 NT
intron within 414P NT
exon within 325C T
exon within 509C T
Upstream 0.9 HC1707-
1
T Y Murakami et al.; GUT; 2005
intron within 350P NT
NA 10-50kb 197P NT
NA within H442 NT Zhaoshi Jiang, Suchit Jhunjhunwala et al.; Genome Research; 2012
intron within 09H-31 T Suzhen Jiang, Ziwei Yang et al.; PLoS One; 2012
Intron2 within 276 NT
Intron2 within 272 T











Zhaoshi Jiang, Suchit Jhunjhunwala et al.; Genome Research; 2012
Wing-Kin Sung et al.; Nature Genetics; 2012
Suzhen Jiang, Ziwei Yang et al.; PLoS One; 2012
Suzhen Jiang, Ziwei Yang et al.; PLoS One; 2012
Zhaoshi Jiang, Suchit Jhunjhunwala et al.; Genome Research; 2012
Wing-Kin Sung et al.; Nature Genetics; 2012
Suzhen Jiang, Ziwei Yang et al.; PLoS One; 2012
Suzhen Jiang, Ziwei Yang et al.; PLoS One; 2012
Wing-Kin Sung et al.; Nature Genetics; 2012
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Table 4.1: List of recurrent genes affected by HBV integration extracted 
from various publications (2000-2012) (Cont’ed)  








Upstream 5.2 83T T Patrizia Paterlini-Brechot et al.;Oncogene; 2003
Downstream 0.3 2A-1 T
Upstream 10.8 83T-A T
Downstream 16 BB3 T
Exon1 within 126 T
Exon1 within 22 T
Intron2 within 268 T
Intron2 within 268 T
Promoter within 266 T
Promoter within 266 T
Promoter within 261 T
Promoter within 261 T
Promoter within 73 T
Promoter within 22 T
Promoter within 46 T
Promoter within 38 T
Promoter within 46 T
Promoter within 81 T
Promoter within 58 T
Promoter within 14 T
Promoter within 92 T
Promoter within 60 T
Promoter within 63 T
Promoter within 34 T
Promoter within 34 T
Promoter within 65 T
Promoter within 64 T
Promoter within 64 T
Intron4/6/8 within 198 T
Intron4/6/8 within 198 T
Promoter/Intron2 within 13 T
Promoter/Intron2 within 13 T
intron within 09H-23 T
NA <10kb 09H-61 T
Promoter 3 10 T
Promoter 0.761 14 T
Promoter 0.387 18 T
Promoter 0.027 33 T
Promoter 0.847 35 T
Promoter 0.55 35 T
Intron14/15/11/7/13 within 98 NT
Intron2 within 70 T
NA 33.921 31656 NT Zhaoshi Jiang, Suchit Jhunjhunwala et al.; Genome Research; 2012
downstream 30 35 T This thesis
Intron1 within 115 T
Intron1 within 115 T
NA <10kb 09H-10 T Suzhen Jiang, Ziwei Yang et al.; PLoS One; 2012
NA 163.053 31107 NT
NA 1456.88 H442 NT
NA within 31107 T
LPHN3 Zhaoshi Jiang, Suchit Jhunjhunwala et al.; Genome Research; 2012
INPP4B Wing-Kin Sung et al.; Nature Genetics; 2012
KIAA0947
KLF13
Wing-Kin Sung et al.; Nature Genetics; 2012
hTERT
Y Murakami et al.; GUT; 2005
Wing-Kin Sung et al.; Nature Genetics; 2012




Table 4.1: List of recurrent genes affected by HBV integration extracted 
from various publications (2000-2012) (Cont’ed) 








Downstream 12 F2T1-4 T
Upstream 26 λYH16 T
Exon 3 within B57 T
Intron 3 within B68 T
Exon 3 within B96 T
NA within 31107 T Zhaoshi Jiang, Suchit Jhunjhunwala et al.; Genome Research; 2012
Exon3 within 70 T
Exon3 within 70 T
Exon3 within 95 T
Exon3 within 95 T
Exon4 within 71 T
Exon6 within 186 T
Exon6 within 186 T
Intron3 within 116 T
Intron3 within 159 T
Intron3 within 116 T
Intron3 within 159 T
Intron3 within 71 T
Intron3 within 49 T
Intron3 within 62 T
Intron3 within 62 T
Intron3 within 53 T
NA 145.417 31107 T
NA 1014.804 H442 T
Upstream 0.4 10A T Y Murakami et al.; GUT; 2005
NA 10-50kb 509P NT Suzhen Jiang, Ziwei Yang et al.; PLoS One; 2012
NA within 31107 T Zhaoshi Jiang, Suchit Jhunjhunwala et al.; Genome Research; 2012
Intron1 within 262 T Wing-Kin Sung et al.; Nature Genetics; 2012
downstream 50 8 NT This thesis
NA 111.654 31656 T Zhaoshi Jiang, Suchit Jhunjhunwala et al.; Genome Research; 2012
Intron5/4 within 108 T
Intron5/4 within 108 T
NA 326.229 31656 NT Zhaoshi Jiang, Suchit Jhunjhunwala et al.; Genome Research; 2012
upstream 6 18 NT This thesis
NA 101.939 31656 NT
NA 14.147 H442 T
Intron1 within 203 T
Promoter within 26 T
Intron within 16A T Y Murakami et al.; GUT; 2005
NA within 31656 NT Zhaoshi Jiang, Suchit Jhunjhunwala et al.; Genome Research; 2012
Intron2 within 177 T
Intron2 within 43 T
Intron2 within 71 T
NA 245.498 31656 NT
NA 5.411 31107 T
Intron1/8/7 within 276 NT
Intron1/8/7 within 272 T
Y Murakami et al.; GUT; 2005
AkihiroTamori et al.; Clinical Cancer Research; 2005
Wing-Kin Sung et al.; Nature Genetics; 2012
MLL4




Wing-Kin Sung et al.; Nature Genetics; 2012
OTOL1
PIK3R1 Zhaoshi Jiang, Suchit Jhunjhunwala et al.; Genome Research; 2012
ROCK1 Wing-Kin Sung et al.; Nature Genetics; 2012
SCARA3
SENP5 Wing-Kin Sung et al.; Nature Genetics; 2012
SMARCA1 Zhaoshi Jiang, Suchit Jhunjhunwala et al.; Genome Research; 2012
ZNF827 Wing-Kin Sung et al.; Nature Genetics; 2012
 
Upstream/Downstream: HBV integrate at the 5' or 3' site of a gene, 
respectively.  
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4.5 HBV as a Highly Mutated Virus 
4.5.1 Frequent Integration and Structural Alteration around 3’-end of 
HBx 
During the course of HBV infection, hepatocytes expressing all viral 
components are continuously being removed or selectively destroyed by viral 
cytopathic effects or host immunological responses [161] probably through 
recognition of the HBcAg other than the HBsAg.  Therefore, hepatocytes 
containing integrated HBV DNA but not expressing full virions, may be 
preferentially retained, leading to increased proportion of integrated HBV 
DNA in long term carriers, including HCC patients who develop HCC decades 
after HBV infection.  
From the analysis of the sites within the viral genome involved in 
integration and structural alterations within the viral genome, we found that 
the region spanning the 3’-end of HBx and the 5’-end of precore/core near the 
DR1 is frequently involved in both the events.  This could potentially result in 
production of HBx C-terminal deletion mutants.  C-terminal deleted HBx 
protein was reported to modulate miRNA expression [252], regulate Wnt-5a 
expression [253], abrogate the growth-suppressive and apoptotic effects of 
full-length HBx [155,156,254], as well as enhance cellular proliferation in 
vitro [156,255] and tumorigenicity in vivo [256,257].  As HBx of different 
extent of deletions were observed, it is still controversial with regards to what 
kind of truncation is responsible for the tumorigenic function of HBx.  We 
observed that in most of the HBx-host chimeric transcripts, the truncation did 
not affect the transactivation domain suggesting that the region spanning the 
start to the transactivation domain of HBx may be the minimal functional unit 
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of the HBx protein.  Interestingly, these C-terminal deletion mutants are also 
observed in the non-tumor samples.  However, the HBx mutant open reading 
frames predicted between the non-tumor and tumor samples are generally 
different with regards to the HBx truncation status and the identity of adjacent 
amino acids coded from the host sequences suggesting that these differences 
may contribute to the difference in the functions of these mutant proteins. 
It is worth mentioning that since the 3’-end of HBx overlaps with the 
core promoter region in the HBV genome, the dominance of these HBx C-
terminal deletion mutants could be due to the selection of cells producing 
reduced or no core antigen (HBcAg) as the HBcAg is a viral target antigen for 
the host immune response [258]. 
4.5.2 Great Sequence Variability within HBV Genome 
In addition to complex structural alterations as well as integration 
events deleting the 3’-end of the HBx gene and generating HBx-host chimeric 
transcripts leading to expression of chimeric proteins, great variability within 
the HBV genomic sequences was also observed.  Notably, significantly more 
non-conservative substitutions especially with respect to Genotype C and in 
the HBx gene were observed.  These non-conservative substitutions may 
change the property/structure of the protein perhaps influencing its 
tumorigenic potential or facilitating their evasion from the host immune 
surveillance.  As there are overlaps between different ORFs of the HBV 
proteins, variation in the DNA sequence may lead to amino acid changes in 
more than one viral protein.  Hence, there may also be co-selection of some 
variants through pressure exerted on another protein. 
126 
Several studies have shown the importance of genotypes and mutations 
within the HBV genome as candidate biomarkers for predicting the risk and 
severity of HCC.  It was reported that different genotypes might differ 
significantly in their responses to therapeutic intervention as well as 
vaccination [16].  Hence it may be important to assess the efficacy of current 
HBV vaccination program against the different HBV genotypes and variants 
and determine whether there is a necessity to customize the therapy or vaccine 
based on the prevalence of specific genotypes or variants in different 
populations.   
Nonetheless, it is worth mentioning that one of the limitations in the 
GS FLX sequencing is the lack of reversible terminator nucleotides that leads 
to problems resolving homopolymeric stretches of sequence [259].  So, runs of 
n nucleotide are occasionally read as n-1 nucleotides.  Hence, during the 
analysis of sequence variations in the HBV genome, the “frameshifted” 
sequences caused by these artefactual “deletions” or “insertions” were not 
included.  This could potentially lead to omitting of some substitution hotspots.  
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CONCLUSIONS 
This study provides a systematic characterization of the in-host 
complexity of the HBV genome, focusing on the HBV integration sites in the 
host genome, the structural alterations and the sequence variations in the viral 
genome, as well as the diversity of HBx transcripts in HCC patients.   
We found that HBV preferentially integrate into promoters of genes in 
tumor samples suggesting that HBV may act as insertional mutagens by 
affecting gene expression rather than the structures of the gene product by 
inserting into the coding sequences.  We also found that HBV integrate more 
frequently into chromosome 10 in the tumor but not the non-tumor samples.  
Significantly, HBV integration into chromosome 10 is associated with poorly 
differentiated tumors.  We also found that HBV integration events in the 
tumor samples affected key genes in cell cycle, cell death and proliferation as 
well as DNA repair.  We therefore propose that HBV integration may simply 
lead to general chromosomal instability and only in rare cases when the 
integration hits a crucial cellular gene then cell carrying those integrations 
with selective growth advantage will expand as cellular clones.  Cells that 
continuously acquired more DNA mutations may eventually develop to 
become tumors.  It also appears that the crucial cellular genes affected by 
HBV integration hence triggering liver cell malignant transformation may 
differ from tumor to tumor giving rise to seemingly random pattern of HBV 
integrations which lead to similar end results. 
Other than integration events disrupting genes related to cell cycle 
checkpoint and DNA repair, the HBx protein is also reported to affect DNA 
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repair pathways and cell cycle checkpoints, both of which are important in 
maintaining genomic integrity.  Therefore, both the cis- and trans- effects of 
HBV may be responsible for triggering genomic instability which may 
contribute to the pathogenesis of HCC.  These also suggest that common 
pathways may be affected by both viral integrations and viral proteins.  
Therefore, identification of common pathways targeted by these two events 
may help to discover pathways that are important in carcinogenesis.   
The HBV genome within HCC patients also shows great sequence 
variation as well as structural alterations, particularly, deletions and inversions 
but rarely duplications possibly giving rise to mutant viral proteins that may be 
implicated in HCC development. 
In conclusion, multiple genetic alterations may be required for the 
development of liver cancer.  This study suggests that HBV integration may 
facilitate one or more of those changes and the functional effects of HBV 
integration may differ from tumor to tumor.  Integration of HBV into the host 
genome has the primary ‘cis’ effect of altering regulations of genes.  Sequence 
variations and structural alterations of HBV genome modifying the viral 
proteins’ structure/function as well as integration events generating novel 
HBx-host chimeric proteins may exert ‘trans’ effect by facilitating the evasion 
of host immune surveillance and/or contributing to tumorigenesis.   
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SIGNIFICANCE AND FUTURE DIRECTION 
To reduce the prevalence of HBV-related HCC cases, the most 
effective way would be to eradicate the virus.  To achieve this, many countries 
have started implementing routine vaccination program for newborns against 
HBV.  However, this does not solve the problem of existing high prevalence 
of chronic HBV infection.  To treat chronic HBV carriers, effective anti-viral 
treatment regimens need to be designed.  Current anti-viral drugs such as 
nucleos(t)ide analogue (NA) therapy only block the HBV DNA replication 
pathway (via inhibiting rt) but have no direct effect on the transcription or 
translation of the Pre-S1/Pre-S2/S and X genes [260] which have been 
reported to be implicated in HCC.  In addition, due to the high variability in 
HBV genome, the treatment efficacy may be compromised.  Therefore, it is 
extremely important to investigate the possible mechanisms by which HBV 
contributes to HCC to prevent this virus from causing threat to the host.  
Previous understanding on HBV was based on low resolution and low 
throughput methods such as southern blots and PCR.  With the invention of 
sequencing technology, the viral genome could then be sequenced and the 
integrated viral genome could also be determined by the DNA fragments 
carrying both viral and cellular sequences.  However, due to the heterogeneity 
of viral genome in HCC patients, molecular cloning was required to isolate the 
different variants.  More often than not, these methods involve PCR which 
require priori knowledge on the viral sequences that are integrated.  In this 
PhD work, we have developed a strategy to enrich for HBV DNA sequences 
from HCC patients using HBV probes that span the 3.2 kb viral genome with 
<60 bps distance between probes, thus resolving the problems associated with 
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PCR-based methods.  The advent of UHT sequencing technology also allows 
us to sequence the HBV-enriched DNA without the necessity of laborious yet 
incomprehensive molecular cloning.  
With the more comprehensive UHT sequencing method, this work 
suggests that HBV integration into the host genome may not be entirely 
random, but favors regulatory regions such as promoters as well as 
chromosome 10.  We also found that integration into chromosome 10 is 
associated with poorly differentiated tumors, highlighting the clinical 
significance of these viral integration events.  Consolidating the integration 
sites identified in this study and currently available integration sites in the 
literature, we found that the TERT gene is one of the most frequent targets of 
HBV integration followed by MLL4 and FN1 suggesting that integration into 
these few genes may be directly implicated in HBV-related 
hepatocarcinogenesis.   
On the virus end, in agreement with several recent comprehensive 
studies on HBV integration, we found that the region within the viral genome 
frequently involved in integration into the host genome is located within the 
DR1 and DR2, closer to the DR1 which is where the virus 
replication/transcription initiates.  In addition, we found that the same region 
is also enriched for structural alterations within the viral genome such as 
deletions and inversions.  Taken together, these observations suggest that both 
the viral integration as well as structural alteration events may occur via viral 
replication/transcription intermediates.  As these events may play some roles 
in contributing to hepatocarcinogenesis, it may be helpful to prescribe anti-
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viral therapies that prevent viral replication/transcription as early as possible in 
the course of HBV infection to probably help prevent HCC development.   
We also presented the single amino acid substitution profiles of the 
four major HBV proteins, which revealed novel substitution hotspots in 
addition to previously reported ones.   
Moreover, we found that the HBx-host chimeric transcripts are the 
most commonly expressed chimeric transcripts in HCC patients suggesting 
that these chimeric transcripts may play important role in HCC development.   
This thesis thus provides an overview of the status of the HBV in HCC 
patients and suggests that the virus genome is highly complex and 
heterogeneous in human host, either at the structural or nucleotide level.  It is 
not clear though whether the integration events or alterations within the HBV 
genome arose from a single clone or multiple clones within a tumor mass of 
heterogeneous origin.  Therefore, in the future, similar studies should focus on 
sampling multiple sites within the same tumor mass for sequencing to assess 
whether the multiple integration sites/structural alterations/sequence variations 
observed in each samples are derived from single or multiple clones.  
Similarly, as multiple forms of HBx transcripts are present within the same 
samples, the abundance of these different forms may be quantified and 
introduced in their natural proportions into untransformed liver cell lines to 
assess the combined effects of these different forms of HBx transcripts on 
cellular transformation.  These works may provide more insights on the role of 
this oncogenic virus in human host. 
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Although there have been reports about correlation between HBV 
genotypes and risk of progression to chronic infection, in Singapore, this 
information is still lacking.  As a country with high prevalence of HBV 
infection, it is therefore important to genotype a larger cohort of HCC patients 
in order to determine the predominant HBV genotypes and whether there is a 
correlation between HBV genotype and response to antiviral therapy, risk of 
progression to chronic infection or even HCC.  It is also important to 
determine if patients infected with multiple HBV genotypes can result in more 
severe liver disease.  If there is any convincing evidence showing the 
correlation between genotypes and clinical outcomes, HBV genotyping may 
need to be included in the clinical evaluation of patients and treatments may 
need to be tailored accordingly. 
In conclusion, HCC remains an extremely complex disease with poor 
prognosis although various causative agents have been identified.  The 
geographic variation in etiology implies that efforts and information from 
different regions of the world are needed in order to fully elucidate the diverse 
mechanisms involved in HCC pathogenesis to better manage and hopefully 
prevent the highly malignant disease. 
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Appendix A Demographic and Clinicopathologic Characteristics of 144 
HCC Patients 






































Normal liver cirrhosis (%)
Yes 39.6
No 42.4
Unknown 18.1  
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Appendix B Quality of Genomic DNA Extracted from 48 HCC Patients 
22
N    T    N     T    N    T    N    T    N    T    N    T     N    T    N    T    N    T 
16 6 9 44 29 21 18 13
38
N    T    N     T    N    T    N    T    N    T    N    T     N    T
10 2 4 8 23 42
24
N    T    N     T    N    T    N    T    N    T    N    T
31 43 41 39 3 27
N    T    N     T    N    T    N    T    N    T    N    T     N    T    N    T    N    T 
17 30 32 35 46 33 45 20
25
N    T    N     T    N    T    N    T    N    T    N    T     N    T    N    T
26 5 15 28 1 37 19 40
N    T    N     T    N    T    N    T    N    T    N    T     N    T    N    T    N    T 





Appendix C Sonicated Genomic DNA from 48 HCC Patients 
N    T     N     T    N     T    N     T    N     T  
3 5 6 1 2
N    T     N     T    N     T    N     T    N     T    N    T     N    T     N    T     N     T
9 10 11 12 13 16 19 22 25
N     T    N     T    N     T    N    T     N    T     N    T     N     T
18 20 23 24 27 31 32
N    T     N     T    N     T    N     T    N     T    N    T     N    T     N    T     N     T
21 26 28 29 33 35 36 37 38
N     T    N     T    N     T    N     T    N    T     N    T  
40 41 42 43 44 45
N    T     N     T    N     T    N     T    N     T    N    T     N    T     N    T     N     T
8 14 15 17 34 39 46 47 48

















Appendix E Summary of Gross Structure of HBx Gene in 49 HCC 
Patients 
NT T NT T NT T
1 - + +
2 + - + + -
3 + - +
4 - - + + -
5 + +
6 - - + +
7 + - +
8 + +
9 + - +
10 + - +
11 + + +
12 + - +
13 + - - -
14 + - +
15 + +
16 + - +
17 + +
18 + +
19 + - +
20 - - + +
21 - + + +
22 + + +
23 - - + + -
24 + - + +
25 + - + +
26 - - + +
27 + - +
28 - - + +
29 - + +
30 + - + +
31 + - + - -
32 + - +
33 - - - - - -
34 + +
35 - - + +
36 - + +
37 + +
38 + +
39 + - +
40 + - - -
41 - - - - - -
42 - - + - -
43 - - + +
44 + + +
45 - - - + -
46 + + +
47 - - + - - -
48 - - - - - -
49 - - - - - -
































































































































































































































































































































Legend: “+”: patient sample positive for amplicon; “-”: patient sample 
negative for amplicon; Blank – not analyzed. 
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1 C8A Intron Intron 1 within PRKAA2 TSG 141 downstream
2 BBS5 Promoter 3 upstream DPP4 TSG 7402 upstream
2 LOC100507581 Promoter 4 upstream BCL2L11 OG 514 upstream
2 ERBB4 Intron Intron 1 within ERBB4 OG Intron 1 within
2 TRNAI-UAU Intergenic 9 upstream EPAS1 TSG 3496 upstream
3 SEC62 Intron Intron 5 within PHC3 TSG 102 downstream
3 OTOL1 Intergenic 6 upstream PPM1L TSG 420 downstream
3 ZBTB20 Intron Intron 4 within DRD3 OG 615 upstream
3 YEATS2 Intron Intron 13 within THPO OG 613 downstream
3 LOC100128160 Intergenic 193 upstream FOXP1 TSG 440 upstream
5 ASSP10 Intergenic 140 downstream PPP2R2B TSG 1219 downstream
5 CENPK Intron Intron 5 within RAD17 OG 3826 upstream
6 HMGCLL1 Intron Intron 6 within KRAS1P OG 675 downstream
7 SLC26A5 Intron Intron 18 within ARMC10 TSG 277 downstream
8 NRG1 Intergenic 50 downstream WRN TSG 1663 downstream
8 LOC100130767 Intergenic 19 downstream IKBKB TSG 1199 downstream
9 BAAT Intron Intron 1 within TMEFF1 TSG 802 downstream
10 Loc100128586 Intergenic 500 upstream UBE2D1 TSG 810 upstream
10 SORCS3 Intergenic 268 downstream NEURL TSG 1941 downstream
11 LRRC55 Intergenic 3 downstream CTNND1 OG 565 upstream
11 PDGFD Intergenic 300 upstream MMP12 OG 1592 upstream
12 ETNK1 Intergenic 120 downstream KRAS OG 2394 downstream
12 PGBD3P1 Intergenic 113 downstream LRIG3 TSG 2426 upstream
13 NBEA Intron Intron 38 within STARD13 TSG 2118 upstream
14 PRKCH Intron Intron 9 within HIF1A OG/TSG 219 upstream
14 Loc100128921 Intergenic 47 downstream EGLN3 TSG 324 upstream
14 FLRT2 Intergenic 976 downstream RAB42P OG 3289 upstream
15 TRPM1 Intergenic 20 upstream TJP1 TSG 1299 upstream
15 GCOM1 Intergenic 25 downstream ADAM10 TSG 854 downstream
16 C16orf78 Intergenic 29 upstream BRD7 OG 960 upstream
17 Loc100128713 Intergenic 60 upstream TOM1L1 OG 1012 upstream





Non-coding RNA - within PIK3C3 TSG 2590 upstream
18 CDH7 Intergenic 500 upstream CDH19 TSG 1217 downstream
19 KPTN/NAPA* Promoter/3'UTR* 4/3'UTR* upstream GLTSCR1 TSG 105 downstream
19 SIPA1L3 Intron Intron 2 within SPINT2 TSG 194 upstream
20 C20orf108 Intergenic 30 upstream AURKA TSG 40 downstream
21 BAGE2&BAGE3 Intergenic 10 upstream TPTE TSG 78 upstream
22 MYO18B Intron Intron 39 within MYO18B TSG Intron 39 within





Nearest Gene Nearest Cancer-related Gene




Appendix F Genes and Cancer-related Genes at or in the Vicinity of 













1 PRDM2 Intergenic 271 downstream PRDM2 TSG 271 downstream
2 RBMS1 Intergenic 188 upstream RBMS1 OG 188 upstream
2 RDH14 Intergenic 258 downstream RHOB OG 2169 upstream
3 FANCD2 Intron Intron 26 within VHL OG 71 upstream
4 LOC389223 Intergenic 30 upstream PCDH10 TSG 1808 downstream
4 CYCSP14 Intergenic 807 upstream PHF17 TSG 1954 downstream
4 CCNA2 Intron Intron 2 within CCNA2 TSG Intron 2 within
4 TRAM1L1 Intergenic 66 downstream SYNPO2 TSG 1872 upstream
4 CCNA2 Intron Intron 2 within CCNA2 TSG Intron 2 within
4 LOC100289626 Intergenic 193 upstream PCDH10 TSG 2713 downstream
4 RPL17P20 Intergenic 21 downstream HOPX TSG 50 upstream
5 ZDHHC11 Intron Intron 11 within TERT OG 364 upstream
5 TERT Promoter 3 upstream TERT OG 3 upstream
5 SLC6A3 Intergenic 11 upstream TERT OG 161 upstream
5 TERT Promoter 0.761 upstream TERT OG 0.761 upstream
5 TERT Promoter 0.387 upstream TERT OG 0.387 upstream
5 TERT Promoter 0.027 upstream TERT OG 0.027 upstream
5 KIAA0947 Intergenic 30 downstream IRX1 TSG 1919 downstream
5 TERT Promoter 0.847 upstream TERT OG 0.847 upstream
5 TERT Promoter 0.55 upstream TERT OG 0.55 upstream
6 TRDN Intergenic 18 upstream HSF2 OG 1221 downstream
7 SLC26A5 Intron Intron 18 within ARMC10 TSG 277 downstream
8 GDF6 Intergenic 28 upstream SDC2 TSG 305 upstream
8 HGSNAT Intergenic 26 downstream IKBKB TSG 903 downstream
8 PRKDC Intron Intron 76 within CEBPD TSG 49 upstream
8 HEV1 Intergenic 9 downstream TPD52 OG 280 downstream
8 TG Exon Exon 37 within WISP1 TSG 177 upstream
9 UBAP2 Intron Intron 12 within PTENP1 TSG 271 upstream
9 TUSC1 Intergenic 591 upstream TUSC1 TSG 591 downstream
10 BTAF1 Intron Intron 34 within HHEX OG 666 upstream
10 CYP2C8 Intergenic 50 upstream PLCE1 TSG 791 downstream
10 C10orf129 Intergenic 11 upstream PLCE1 TSG 855 downstream
10 ATRNL1 Intron Intron 26 within TCF7L2 TSG 2396 downstream
10 REEP3 Intergenic 85 downstream EGR2 TSG 891 upstream
10 NCOA4/MSMB# Promoter/Intron# 3/Intron 3# upstream MSMB TSG Intron 3 within
10 ADARB2 Intron Intron 1 within GTPBP4 TSG 637 downstream
10 ADARB2 Intron Intron 1 within GTPBP4 TSG 637 downstream
10 LIPF Intergenic 12 downstream ACTA2 TSG 245 downstream
10 FAS Intron Intron 7 within FAS TSG Intron 7 within
11 RPS3 Intergenic 7 upstream UVRAG TSG 422 upstream
11 AIP Intron Intron 5 within AIP TSG Intron 5 within
14 POLE2 Intron Intron 9 within RPS29 TSG 77 upstream
15 MYO9A Intergenic 1 downstream NEO1 TSG 1228 upstream
17 CDK12 Intron Intron 10 within PPP1R1B TSG 108 upstream
17 LOC100129683 Intergenic 44 downstream MAP2K3 OG 1031 downstream
17 MAP2K4 Intergenic 65 downstream MAP2K4 TSG 65 downstream
17 NTN1 Intron Intron 6 within NTN1 TSG Intron 6 within
17 KRT32 Exon Exon 6 within KRT14 OG 119 downstream
17 MSI2 Intergenic 18 upstream NOG TSG 643 downstream
18 ALPK2 Intron Intron 1 within MIR122 TSG 163 downstream
18 FGF7P1 Intergenic 22 upstream PTPN2 TSG 2028 upstream
18 GATA6 Intergenic 19 downstream RBBP8 TSG 712 upstream
18 GATA6 Intergenic 19 downstream RBBP8 TSG 712 upstream
19 ZNF607 Intergenic 9 upstream HKR1 OG 364 downstream
20 DEFB132 Promoter 1 upstream NRSN2 TSG 90 upstream
X MUM1L1 Intergenic 5 downstream CLDN2 TSG 706 upstream










OG: Oncogene; TSG: Tumor Suppressor Gene; Upstream/Downstream: HBV 
integrate at the 5' or 3' site of a gene, respectively. 
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Appendix G Open Reading Frame Prediction from HBV-host Chimeric 









Appendix G Open Reading Frame Prediction from HBV-host Chimeric 











Appendix H Expression of HBx Protein in 103 HCC Samples 
102 84 111 5 96 12
2217 18 1915 16 20 211413
2624 28 30 322925 3127 33
434035 3934 41 4236 37 38
6362616044 45 47 48 5346
65 66 67 68 6964 70 71 72 73
74 8478 85 8675 8376 79 87
979492919088 89 93 95 96
101 105103102 10498 100 10699 107




















































































































































































































Appendix I Permission to reproduce text/data/figures from IARC, 
Nature Medicine, GUT, Journal of Hepatology and 
Carcinogenesis 
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